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The neuronal ceroid lipofuscinoses (NCLs) are a group of pediatric neurodegenerative 
syndromes. They are characterized by epilepsy, mental and motor regression, loss of vision 
and early death. Pathological findings include accumulation of lysosomal storage material 
together with neuron loss and glial activation in affected brains. Mutations in at least ten 
genes are reported to cause NCL disease. Apart from human disease, NCL phenotypes are 
widely present in the animal kingdom. However, the events leading to NCL disease onset and 
progression remain elusive and without a possibility to intervene. 
In this study these events were assessed in two forms of NCLs, the CLN8 and CLN10 
diseases. Late-infantile onset CLN8 disease and the more protracted progressive epilepsy with 
mental retardation are caused by mutations in the CLN8 gene. CLN8 is a resident of the 
endoplasmic reticulum membrane and linked to a lipid metabolism-related protein family. 
Mutations in the cathepsin D (CTSD) gene cause the most severe form of NCL, CLN10, which 
typically leads to death shortly after birth. The lysosomal aspartic protease CTSD is involved 
in cellular protein degradation and apoptosis. Two animal models were used in this study, the 
Cln8mnd mouse carrying a spontaneous mutation in the mouse Cln8 gene, and the previously 
generated cathepsin D deficient Drosophila, cathD1. Both model the respective human NCL 
diseases with intracellular storage and neuronal death. 
The Drosophila cathD1 was characterized with degenerative changes in the retina. This 
phenotype could be utilized to study the genetic pathways of cathD in a hypothesis-based 
modifier screen using Drosophila genetics and histological techniques. Seven candidate 
modifiers involved in lipid metabolism regulation, endocytosis and oxidative stress were 
identified as enhancers of the retinal degeneration of cathD1. Similar processes have been 
described affected in other Drosophila models for NCLs, suggesting that Drosophila NCL 
proteins may act in overlapping genetic pathways. While the importance of these pathways 
needs to be assessed in the human disease, their overlap suggests a possibility for a common 
mechanism of neurodegeneration. 
Similarly to previously characterized NCL models, the CLN8 disease model Cln8mnd showed 
neuron loss and glial activation in sensory thalamocortical pathways. By using stereological 
methods and histology, neuron loss in the visual thalamocortical pathway was shown to 
appear relatively late compared to the previously described retinal degeneration in Cln8mnd. 
This suggests that the visual areas of the brain are spared even with diminished or absent 
input from the retina. The somatosensory thalamocortical pathway was affected first. While 
the cerebral cortical sensory areas were relatively spared, neuron loss progressed rapidly in the 
thalamic component of these pathways. Thalamic sensory nuclei have shown particular 




proceeding from thalamus to the cortex. In the future, knowledge of the differentially 
affected components of distinct pathways may be utilized in therapies, which should be 
targeted to the primary sites of pathology. In CLN8 disease these appear to be the retina and 
somatotosensory thalamus. 
Glial cells were observed to contribute to the Cln8mnd neuropathology. Especially microglial 
activation preceded neuron loss in Cln8mnd brain. Decreased axonal myelination, studied by 
stereology, light and electron microscopy, was observed even before microglial activation, yet 
myelination reached normal levels by the time of major brain pathology. By protein and gene 
expression profiling we were able to show a delayed maturation of oligodendrocytes in the 
Cln8mnd mouse brain and in vitro. These results suggest that perturbations in the glia-neuron-
glia signaling occur well in advance of the neurodegeneration in Cln8mnd. With increasing 
information on the mechanisms of these interactions it may be possible to find a specific 
target for therapies for CLN8 or NCLs in general. 
The myelination defect in Cln8mnd was observed through large-scale brain lipid analysis, where 
decreased amounts of myelin-specific galactolipids were found in Cln8mnd cortex, especially in 
the early stages of Cln8mnd disease. Subsequent analyses showed a persistent defect in the 
galactolipid synthesis by the UDP-galactose:ceramide galactosyltransferase enzyme. The 
connection of CLN8 to lipid synthesis regulation is in agreement with the sequence-based 
hypothesis of a role for CLN8 in lipid metabolism regulation, while further studies are 
required to indicate a specific function. 
In conclusion, this study resulted in increased knowledge on the CLN8 and CLN10 disease 
pathogenesis and on the cellular functions of the affected proteins. Results from both cathD1 
Drosophila and Cln8mnd mouse suggest both similarities and differences to other NCL models. 
In the future, increased knowledge on the molecular changes may take us towards targeting 






Neuronaaliset seroidilipofuskinoosit (NCL-taudit) muodostavat yleisimmän syyn lapsuusiän 
hermorappeumaan. Vaikka tautien taustalla olevat geenivirheet pääosin tunnetaankin, 
molekyylitason tapahtumat, jotka johtavat taudin syntyyn, ovat edelleen pitkälti selvittämättä. 
Taudin etenemistä ei myöskään kyetä pysäyttämään tai tautia parantamaan.  
Tässä väitöskirjassa tutkittiin NCL-tauteihin lukeutuvien CLN8- ja CLN10-tautien taustalla 
olevien proteiinien toimintaa. Synnynnäisen NCL-taudin, CLN10:n taustalla ovat katepsiini D 
(CTSD) –geenin virheet. Solun sisällä lysosomeihin paikantuva CTSD on proteiineja pilkkova 
entsyymi. Työssä käytimme apuna CTSD-poistogeenistä banaanikärpästä (cathD1), jolla on 
NCL-taudeille tyypillistä solunsisäistä kertymämateriaalia ja hermosolujen rappeumaa. 
Teimme seulonnan, jossa tarkastelimme 17 geenin mutaatioiden vaikutusta cathD1-kärpäsen 
ilmiasuun. Histologiseen analyysiin perustunut seulonta vahvisti, että cathD1:n solukuolema 
voimistuu, kun kärpäsellä on häiriöitä rasva-aineenvaihdunnassa, endosytoosissa ja solujen 
suojautumisessa happiradikaaleilta. Samankaltaisten reittien on havaittu vaikuttavan myös 
muiden NCL-banaanikärpäsmallien ilmiasuihin. Näitä reittejä voidaan tarkemmin tutkia 
banaanikärpäsessä ja muissa NCL-tautien solu- ja eläinmalleissa. 
CLN8-geenin mutaatiot voivat aiheuttaa paitsi lapsuusiän NCL-taudin, myös nuoruusiällä 
puhkeavan, suomalaisen tautiperimän tauteihin kuuluvan Pohjoisen epilepsian. CLN8-
toiminta on tuntematon, mutta proteiinin tiedetään paikantuvan solujen 
endoplasmakalvostoon ja sekvenssiyhtäläisyyksien perusteella sen on arveltu liittyvän rasva-
aineenvaihdunnan säätelyyn. Tautimallina CLN8-tutkimuksissa käytettiin Cln8mnd-hiirikantaa, 
jossa on luonnollisesti syntynyt Cln8-geenin mutaatio. CLN8-taudin etenemistä tutkittiin eri-
ikäisistä hiiristä kerätyissä aivoleikkeissä ja käytettiin kvantitatiivisia menetelmiä, joiden avulla 
saatiin luotettava kuva hermosolukuoleman laajuudesta. Näyttääkin siltä, että aiemmin 
kuvattujen NCL-tautimallien lisäksi myös Cln8mnd-hiiren aivopatologia keskittyy isoaivokuoren 
ja talamuksen välisiin yhteyksiin ja alkaa tunto- ja kipuaistimuksia välittävältä 
somatosensoriselta aivoradalta. Toisin kuin useissa aiemmin kuvatuissa NCL-malleissa, 
aivojen näköaivorata säilyi vahingoittumattomana hyvin pitkään, vaikka Cln8mnd-hiiren 
tiedetään sokeutuvan varhain. Tietoa tautimuutosten etenemisestä voidaan toivottavasti 
käyttää hyväksi, kun pyritään kehittämään hoitomuotoja CLN8-tautia vastaan. 
Muutokset glia- eli hermotukisoluissa edelsivät hermosolukatoa tutkituilla aivoalueilla. Jo 
varhain ennen hermosolukuolemaa havaittiin aivojen immuunipuolustuksen aktivaatioon 
viittaavia muutoksia mikrogliassa. Vielä aiemmin muutoksia nähtiin oligodendrosyyteissä, 
jotka muodostavat hermosolujen viejähaarakkeita ympäröivän myeliinitupen. Myeliiniä, joka 
on välttämätöntä nopealle signaalinvälitykselle, muodostui Cln8mnd-hiirellä normaalia 




vähentyneeseen valmistukseen. Tulokset viittaavat siihen, että CLN8:n toiminta liittyisi rasva-
aineiden valmistukseen, mutta lisätutkimuksia tarvitaan, jotta pystyttäisiin selvittämään tarkka 
biologinen mekanismi. 
Väitöskirjatyön tuloksena saatiin lisää tietoa NCL-tautien aiheuttamasta aivopatologiasta ja 
siihen vaikuttavista tekijöistä. NCL-taudit ovat keskenään hyvin samankaltaisia. Tämä 
tutkimus tukee oletusta, että tautimekanismeissa on samankaltaisuuksia. Esimerkiksi rasva-
aineenvaihdunnan häiriöiden havaittiin vaikuttavan sekä CLN8- että CLN10-tautimalleissa. 
Tautimekanismit ovat kuitenkin myös hyvin erilaiset, mikä nähtiin vertailtaessa eri NCL-
malleissa tehtyjä tutkimuksia isoaivokuoren ja talamuksen välisistä radoista: NCL-taudit eivät 
noudata samaa kaavaa siinä, miltä alueilta tautimuutokset alkavat. Näiden vertailujen kautta 






I said in Dorian Gray that the great sins of the world take place in the brain: but it 
is in the brain that everything takes place.... It is in the brain that the poppy is 
red, that the apple is odorous, that the skylark sings. 
-Oscar Wilde 
 
Why do we have a brain? As Oscar Wilde says, to see, to smell, to hear. With a nervous 
system we are able to observe the environment with senses such as sight, smell, hearing, taste, 
touch, pain, and balance. Sensations arouse a diversity of behaviours: in Wilde’s case, he got 
an idea, took a pen and wrote, performing the acts of the human brain. Performed acts – that 
is the other half of the answer. We have a brain to act according to our perceptions of the 
environment. Sometimes the act is deliberate, directed movement such as the movement of 
fingers and hands. Sometimes the result is a chain of reasoning, consideration of previous 
experiences, leading to the conscious decision not to act. 
Why study the nervous system of another animal species in order to understand the human 
brain? We may do so out of pure curiosity, since in evolution many variations have been 
generated to adjust to environmental challenges. Yet with shared environment and ancestors 
many of the adjustments are similar between us animals. That is what we make use of when 
tackling a certain problem in an experimental model organism. Brains of different species do 
have much in common: they are comprised of nerve cells, neurons, which signal electrically 
and are interconnected via synapses, structures that join the cells together and enable signal 




Figure 1. Drawings of Santiago Ramón y Cajal depicting the organization of the visual system (from left to right) of a vertebrate, a cephalopod (Sepia) and an 
insect (housefly, Musca). This illustration shows the physical dimensions of the neuronal circuits: vertebrate neurons are larger than those of a cephalopod which 




2 REVIEW OF THE LITERATURE 
2.1 CELL TYPES OF THE CENTRAL NERVOUS SYSTEM 
… l'écorce cérébrale est pareille à un jardin peuplé d'arbres innombrables, les 
cellules pyramidales, qui, grâce à une culture intelligente, peuvent multiplier 
leurs branches, enfoncer plus loin leurs racines, et produire des fleurs et des fruits 
chaque fois plus variés et exquis. 
… the cerebral cortex is similar to a garden filled with trees, the pyramidal cells, 
which, thanks to intelligent culture, can multiply their branches, sending their 
roots deeper and producing more and more varied and exquisite flowers and 
fruits. 
-Santiago Ramón y Cajal 
 
The fact that the brain is formed by a network of connected but separate individual cells that 
communicate specifically with each other was demonstrated by Santiago Ramón y Cajal, 
Nobel Prize laureate in Physiology or Medicine, 1906. Ramón y Cajal described and illustrated 
a plethora of nervous system cell types, subtypes and the pathways they formed. He utilized a 
variety of organisms in his work, including material from humans and other mammals, birds, 
frogs, cephalopoda and insects, and had a substantial contribution to the field of comparative 
neuroanatomy (Fig. 1). 
Ramón y Cajal’s work was the basis of the Neuron Doctrine, the principle of the neuron as 
the single anatomical and functional unit in the nervous system. Ramón y Cajal also 
acknowledged the other major cells types in the nervous system, collectively called the glia, by 
speculating on their functions in attention, sleep and wakefulness (Garcia-Marin et al. 2007). 
However, until recent decades, glial cells have mostly been regarded as connective tissue and 
named as the ‘nerve glue’ (Virchow 1846; according to (Baumann & Pham-Dinh 2001). While 
the active roles of glial cells are still being discovered, neurons are no longer considered as the 
single functional units of information flow in the brain - they are aided to a great extent by 
glial cells in forming and maintaining neural circuits. Established functions of glia include 
supporting neurotransmission, maintaining ionic balance in the extracellular space, and 
insulating axons to speed up electrical communication (Allen & Barres 2009). The main cell 
types of the vertebrate central nervous system (CNS), the astrocytes, oligodendrocytes, 
microglia and neurons (Fig. 2) are introduced in the following sections 2.1.1-2.1.4. Notes on 





Figure 2. The four main cell types of the vertebrate central nervous system. A) Schematic illustration 
of a neuron, myelin forming oligodendrocyte, an astrocyte and a microglial cell. B) Neurons and glial 
cells observed through antibody-based staining methods. Scale bars 20 µm. 
2.1.1 NEURONS 
Morphologically, a neuron consists of a cell soma (or cell body), one axon and usually several 
dendrites. There are a multitude of neuron types in the vertebrate nervous system. 
Classification relies on the cellular morphology, electrophysiology, use of neurotransmitters 
and other chemical properties, and on the synapses and connections they make. However, the 
simplest classification of neurons in the vertebrate nervous system is according to the 
distance of the axon projection. Neurons connecting to more distant parts of the nervous 
system are called projection or relay neurons, and neurons with short-distance axons that 
connect to local circuits are called interneurons (Kandel et al. 2000). In this section, properties 
of mammalian cerebral cortical and thalamic neurons are introduced. 
2.1.1.1 Neurons of the cerebral cortex 
Pyramidal cells (Fig. 3A) are the major projection neurons and the most abundant neuron 
type of the neocortex (70-80% of neurons). In addition, they are the main excitatory neurons 
of the cerebral cortex releasing glutamate or aspartate as neurotransmitters. Pyramidal 
neurons are identified by their large size, triangular-shaped soma, large number of dendrites 
and dendritic spines and highly polarized shape. However, their structure exhibits high 
regional variation. Spiny stellate cells are another excitatory cell type of the cortex, but as 
opposed to pyramidal neurons, they are local interneurons. (Elston 2003; Markram et al. 2004; 





Figure 3. Neuron subtypes in the cerebral cortex and thalamus. A) Excitatory pyramidal cells project 
to the spinal cord, subcortical and to other cortical regions. B) Large basket cells (LB), double bouquet 
cells (DB) and chandelier cells (Ch) are illustrated surrounding a layer III pyramidal neuron. C) 
Thalamocortical relay neurons (TCR) receive information through afferent neurons (Aff) and project 
to cortical regions (Ctx), sending collateral projections to thalamic reticular nucleus (Rt). The reticular 
nucleus also receives collaterals from the cortical axons projecting to thalamus. Local interneuron (in) 
is also depicted. Illustrations modified from (DeFelipe 2011; Jones 2009; Squire et al. 2003). 
 
The major inhibitory neurons of the cerebral cortex include the basket cells, chandelier cells 
and double bouquet cells (Fig. 3B). They predominantly synapse with pyramidal cells and use 
gamma-aminobutyric acid (GABA) as the neurotransmitter. These GABAergic interneurons 
can be distinguished by their morphological, electrophysiological and molecular properties. 
Especially the calcium-binding proteins parvalbumin, calbindin and calretinin serve as valid 
molecular markers. Approximately 50% of all inhibitory interneurons are basket cells, which 
are further divided into large, small and nest basket cells. They target the somata and proximal 
dendrites of pyramidal cells and are thus considered to control the integrated synaptic 
response. Meanwhile the chandelier cells target the axons where they give a strong inhibitory 
input. Double bouquet cells target the pyramidal cell dendrites. (Markram et al. 2004; Squire et 
al. 2003) 
The cerebral cortical layers differ according to which neuron types they contain (Fig. 3A and 
section 2.3.1.1). Pyramidal cells are mainly located in layers III, V and VI. Spiny stellate cells 
are most highly concentrated in layer IV of primary sensory areas. The basket cells, chandelier 
cells and double bouquet cells predominately localize in layers III and V where they inhibit 




2.1.1.2 Neurons of the thalamus 
The thalamus is an important relay system between the cerebral cortex and other regions of 
the CNS. Mammalian thalamic nuclei contain excitatory relay neurons and local interneurons 
(Fig. 3C). The thalamic reticular nucleus consists of GABAergic interneurons and acts to 
integrate and modulate information received and sent by the thalamus. While many thalamic 
nuclei of mice and rats appear to lack local interneurons, the major inhibitory action is 
executed by the reticular nucleus (Arcelli et al. 1997). The thalamic relay neurons largely share 
a common morphology, including a symmetrical, bushy dendritic field. Interneuronal 
dendrites show rich terminal branching and swellings, while the discoid dendritic arbors of a 
reticular interneuron are situated in the plane of the cell nucleus. (Jones 2009; Sherman & 
Guillery 2006) 
The importance of the thalamic communication with cortex is illustrated by the synaptic input 
it receives: the majority of inputs to a typical sensory relay neuron are from cerebral cortex 
(almost 50% of the synapses) while the inputs from the sensory receptors account only for 5-
15% of the synapses. A large number of inhibitory inputs is mostly derived from the reticular 
nucleus (approximately 30% of the synapses). Similarly, cortical inputs predominate in the 
reticular nucleus cells, where 70% of synapses are from the cortex. (Jones 2009; Van Horn et 
al. 2000) 
2.1.2 ASTROCYTES 
Astrocytes populate all CNS regions and constitute the most abundant cell type in the brain. 
Astrocytes form networks through gap junction channels that allow intercellular information 
flow, such as the calcium (Ca2+) transients that may serve as a means of communication 
within and between astrocytes, other glial cells and neurons. Astrocyte morphology, functions 
and molecular expression pattern changes during CNS injury or disease in a process of 
reactive astrocytosis. (Allen & Barres 2009; Giaume et al. 2010; Sofroniew & Vinters 2010) 
2.1.2.1 Astrocyte morphology and functions 
In normal brain, astrocytes can be divided into at least two phenotypes: protoplasmic 
astrocytes are found in grey matter and fibrous astrocytes in white matter. The less studied 
fibrous astrocytes contact neuronal axons at the nodes of Ranvier. Protoplasmic astrocytes 
form a few main branches that give rise to several processes which contact neuronal 
dendrites, synapses and other astrocytes. (Sofroniew & Vinters 2010) 
With their close contacts to synapses, it is not surprising that astrocytes have various roles in 
the synapse. They recycle neurotransmitter molecules released to the synaptic cleft through 




efficiently removed and inactivated. In addition, astrocytes release molecules such as 
thrombospondins, to induce synaptogenesis and increase synaptic activity. Astrocytes are 
proposed to modulate neuronal excitability through releasing 'gliotransmitters' glutamate, 
adenosine triphosphate (ATP) and D-serine. There are neuronally evoked fluctuations in the 
astrocytic Ca2+ concentration that have been proposed to trigger gliotransmitter exocytosis to 
the synaptic cleft. However, the debate continues on the significance of this phenomenon. 
(Barres 2008; Hamilton & Attwell 2010) 
Besides the synapses, astrocytes contact the blood vessels and form an imperative part of the 
neurovascular unit comprising neurons, glia and vascular cells (endothelia, pericytes and 
vascular smooth muscle cells). Astrocytes regulate the cerebral microcirculation through 
inducing vasodilation/vasoconstriction, possibly depending on the neuronal activity and 
involving Ca2+ waves in astrocytes. While astrocytes act as the main glycogen storage in the 
CNS, they are likely to participate in the increased metabolic requirements evoked by synaptic 
activity. (Iadecola & Nedergaard 2007; Sofroniew & Vinters 2010) 
2.1.2.2 Reactive astrocytosis 
Reactive astrocytosis is defined as the astrocytic response to all CNS perturbations, 
manifesting as changes of astrocyte molecular expression, morphology and function that 
depend on the severity of the insult (Fig. 4). Astrocytosis is a regulated phenomenon 
including inter- and intracellular signalling. All CNS cell types can release signalling molecules 
to trigger reactive astrocytosis, including growth factors, cytokines and neurotransmitters. 
(Sofroniew & Vinters 2010) 
Morphologically, reactive astrocytes exhibit cellular hypertrophy with thickened processes. 
Reactive astrocytes are characterized by the upregulation of cytoskeletal intermediate filament 
proteins, especially of the glial fibrillary acidic protein (GFAP). In severe astrocytosis, 
proliferative astrocytes may originate from local or migrated glial cell progenitors or as a 
result of the cell cycle re-entry of mature astrocytes. Glial scar formation is a response to 
severe insult requiring a complex interplay of astrocytes with fibromeningeal and other glial 
cells. A glial scar establishes a physical barrier to the site of the injury, restricting the entry of 
inflammatory cells but also preventing axonal regeneration. (Pekny & Pekna 2004; Sofroniew 
2009; Sofroniew & Vinters 2010) 
Reactive astrocytosis can have both beneficial and detrimental effects on neurons and other 
cell types. The beneficial functions have been observed by experiments where reactive 
astrocytosis has been attenuated. Loss of reactive astrocytosis can lead to excitotoxic 
neurodegeneration due to failure in the synaptic glutamate uptake. It also results in enhanced 
synaptic degeneration in response to cortical lesions. Loss of astrocyte barrier functions may 




the production of cytotoxic molecules such as pro-inflammatory cytokines through which 
astrocytosis may lead to chronic inflammation or neuropathic pain. Reactive astrocytosis may 
exhibit two stages, showing beneficial effects in the acute stage after CNS injury, but later 
inhibiting the CNS regeneration and leading to increased inflammation. (Milligan & Watkins 
2009; Pekny & Nilsson 2005; Sofroniew 2009) 
 
 
Figure 4. Different grades and progression of reactive astrocytosis. A) In normal brain, astrocytes 
inhabit separate domains and only some express GFAP (dark grey cells). B) Hypertrophy and 
molecular changes (GFAP expression) are seen in cases such as moderate metabolic or molecular 
insults or milder inflammatory activation. This phenotype can reverse if the triggering insult is 
removed. C) Molecular expression changes, overt cellular hypertrophy and proliferation are typical in 
areas surrounding severe lesions, infection or in regions of chronic neurodegeneration. D) Glial scars 
envelop areas of overt tissue damage and inflammation. It includes proliferation of astrocytes and 
other cell types. Glial scars restrict entry of inflammatory cells (round light grey cells) to the site of 
injury. Illustration based on (Sofroniew & Vinters 2010). 
 
2.1.3 OLIGODENDROCYTES 
In vertebrates, oligodendrocytes are essential for rapid electrical communication between 
neurons and their targets. Oligodendrocytes generate myelin sheets that enclose axons 
enabling the saltatory conduction of action potentials. In addition, myelination induces 
clustering of ion channels thereby further enhancing conduction velocity (Allen & Barres 
2009). Other roles of oligodendrocytes include providing trophic and metabolic support to 
the neuronal axons (Nave 2010). Schwann cells, the peripheral counterparts of 




peripheral nerves and display similarities but also differences to the CNS oligodendrocytes 
(Baumann & Pham-Dinh 2001). 
2.1.3.1 Myelin 
In brain, myelin is formed by the expanded and specialized plasma membrane of a mature, 
myelinating oligodendrocyte. The compactly multilayered and segmented structure of myelin, 
low water content and high lipid content account for its insulation properties. Structurally, 
myelin sheath segments or internodes are separated by the nodes of Ranvier, where myelin is 
lacking and the axon is exposed to the extracellular milieu. Rapid saltatory nerve conduction 
is established through the axonal impulse jumping from node to node over the well-insulated 
internodes. (Baumann & Pham-Dinh 2001) 
Myelin membrane has a protein to lipid ratio of 1:3 while other biological membranes have a 
ratio of 1:1-4:1. The lipid composition is unique (Fig. 5) with exceptionally high proportions 
of glycosphingolipids galactoceramide (cerebroside, GalC) and its sufated form, 
sulfogalactoceramide (sulfatide, sGalC). These lipids differ from other glycosphingolipids 
since they consist of a galactose (instead of glucose) headgroup, they incorporate very-long-
chain fatty acids and they are solid at body temperature. Other major myelin lipids include 
cholesterol, which decreases the fluidity of the membrane, and phospholipids, of which 
ethanolamine-containing plasmalogen is highly myelin-enriched. A large proportion of fatty 
acids in galactolipids and phospholipids are saturated. These lipid characteristics contribute to 
the decreased membrane fluidity and permeability that enhance the insulation capacity of the 
myelin membrane. (Aggarwal et al. 2011; Chrast et al. 2011; Siegel et al. 1999) 
The multilayered myelin membrane is compacted by specific oligodendrocyte expressed 
proteins (Fig. 5). The myelin basic protein, MBP, and the proteolipid-protein, PLP, account 
for 60-80% of total myelin proteins and are the major structural proteins in CNS myelin (Fig. 
5). MBP joins the cytoplasmic membrane leaflets in close apposition. Membrane spanning 
PLP is suggested to function in the adhesion of the extracellular leaflets. (Aggarwal et al. 2011; 
Siegel et al. 1999) 
Synthesis of the myelin components is under strict developmental regulation and needs to 
progress rapidly before and during the active period of myelination (section 2.1.3.2). The 
activity of UDP-galactose:ceramide galactosyltransferase (CGT), catalyzing the last step of 
galactolipid synthesis, increases notably in rodent brain just before the maximal rate of myelin 
formation and then gradually declines. MBP synthesis and integration to myelin is very rapid 
and occurs in free ribosomes associated with the myelin membrane. PLP is synthesized in the 
bound ribosomes in the perikaryon and transported to the oligodendrocyte processes possibly 




of premyelinating oligodendrocyte processes that are released and integrated once the 
myelination is initiated. (Siegel et al. 1999; Simons & Trotter 2007) 
 
 
Figure 5. Major components of the myelin membrane. Cholesterol and galactolipids are enriched on 
the extracellular side of the myelin membrane, while ethanolamine plasmalogen is localized to the 
cytoplasmic side of the bilayer. The cohesive effect of MBP is mainly established through its 
interactions with phosphatidylserine and phosphatidylinositol-(4,5)-bisphosphate. Reprinted from 
Aggarwal et al. 2011, with permission from Elsevier. 
 
2.1.3.2 Oligodendrocyte development and myelination 
Myelination is a spatiotemporally regulated process that requires the oligodendrocytes to 
proliferate, migrate and synthesize myelin membrane. In the mouse CNS, myelin formation 
starts at birth in the spinal cord and optic tract, and by 45–60 days postnatally the brain is 
completely myelinated. In humans the myelination peak occurs during the first year after 
birth, yet the process already starts during the second half of fetal life from the spinal cord. 
Myelination occurs until 20 years of age, especially in the associative areas of the cerebral 
cortex. Myelination progresses caudorostrally in the brain, opposite to the spinal cord where 
the progression is rostrocaudal. (Baumann & Pham-Dinh 2001) 
In the mammalian cortex, oligodendrocytes as well as neurons and astrocytes are generated 
from the proliferating neuroepithelial cells of the telencephalic ventricular and subventricular 
zone (SVZ). Oligodendrocyte progenitors migrate from these zones, continuously extending 
and retracting their processes. This may serve to sense other nearby oligodendrocyte 




oligodendrocytic cells continues throughout postmigratory oligodendrocytic development. 
Different stages of oligodendrocyte development are characterized by changes in cell 
morphology and molecular expression pattern (Fig. 6). (Baumann & Pham-Dinh 2001; 
Simons & Trotter 2007).  
 
Figure 6. Morphological and molecular changes during oligodendrocyte development. 
Oligodendrocyte progenitors have bipolar morphology or extend only a few processes and can be 
detected with markers such as gangliosides (A2B5) and chondroitin sulfate proteoglycan (NG2). These 
cells are migratory and proliferate, also in vitro, in response to specific growth factors and signals. 
Preoligodendrocytes are multiprocessed cells that have mostly lost their mitogenic response to PDGF 
and are post-migratory. An immature oligodendrocyte obtains the marker GalC and loses A2B5 
antigens. A mature oligodendrocyte expresses markers such as MBP, PLP and myelin and 
oligodendrocyte glycoprotein (MOG). Adapted from Baumann & Pham-Dinh, 2001, use permitted by 
the American Physiological Society. 
 
In oligodendrocyte development signals from axons control the timing of progenitor 
differentiation to ensure correct timing of myelination. In addition, they are important in 
matching the number of oligodendrocytes to the axons requiring myelination. Trophic factors 
and growth factors, such as platelet-derived growth factor (PDGF) and fibroblast-derived 
growth factor (FGF), secreted by neurons and astrocytes regulate oligodendrocyte 
proliferation and survival. Myelination is influenced by the electrical activity of neurons, 
possibly through secretion of adenosine from neurons and by indirect signals from astrocytes. 




clustering at the nodes of Ranvier. Oligodendrocytes also modify the axonal cytoskeleton and 
transport. (Simons & Trajkovic 2006) 
2.1.4 MICROGLIA 
Microglia comprise 5-20% of the glial cells in CNS. They derive from the hematopoietic 
lineage, unlike neurons, astrocytes and oligodendrocytes, which all have a neuroectodermal 
origin. Microglia are the resident immune cells of the CNS that survey the brain for damage 
and infection and phagocytose dead cells and debris. Activated microglia are present in most 
if not all neuropathological conditions, but whether they are helpful or harmful in these 
conditions remains mostly an open question. (Allen & Barres 2009) 
Developmentally, microglial cells enter the brain from the blood circulation early in 
development, in both embryonic and early postnatal stages. In the CNS microglial precursors 
proliferate and migrate to populate the CNS. While migrating, microglia differentiate and 
their early developmental amoeboid phenotype is replaced by the ramified state. Neurons 
induce and sustain the ramified state by direct signalling, but also astrocytes and epithelial 
cells affect the change. Even in the ramified state, often misleadingly called the resting state, 
microglia are highly motile cells constantly extending and withdrawing processes. (Hanisch & 
Kettenmann 2007; Tambuyzer et al. 2009). 
The activation of microglia affects their morphology and molecular expression. The gradual 
changes from ramified, surveying microglia to the activated, alert microglia are characterized 
by cellular hypertrophy and thickened processes giving the cells a “bushy” appearance (Fig. 
7). Under a persisting stimulus, microglia acquire the amoeboid morphology and become fully 
functional phagocytotic cells that express molecular markers of macrophages. At this stage, 
there often is another population of macrophage marker expressing cells, the acutely CNS-
infiltrated macrophages. These two types of immune cells are both required for the 
maintenance of CNS integrity. Apart from phagocytosis microglia regulate the immune 
reaction by releasing immunoregulatory substances. Interleukin-1 (IL-1) and tumor necrosis 
factor  (TNF) are major pro-inflammatory cytokines whereas anti-inflammatory cytokines 
include IL-10, transforming growth factor  (TGF) and IL-1 receptor antagonist. (Carson et 
al. 2007; Hanisch & Kettenmann 2007) 
Phagocytotic microglia migrate towards the chemotactic stimulus and proliferate at the target. 
Microglia clear the target cells or debris, such as the remnants of neurons eliminated by 
developmental apoptosis. Microglia are implicated in synaptic remodelling during the 
development of the nervous system, since they have been proposed to remove inappropriate 
synaptic connections through phagocytosis. Microglia are also involved in synaptic 
remodelling during pathological conditions, by efficiently removing excitatory synapses and 




described in spinal motor neurons but may occur in other regions of the CNS as well. (Eroglu 
& Barres 2010; Tambuyzer et al. 2009). 
 
Figure 7. Morphology of the microglia in the rat brain, depicting ramified (A,B), hypertrophied (C,D) 
and bushy cells (E,F). Reprinted from Sołtys et al. 2001, with permission from John Wiley and Sons. 
 
Healthy neurons and possibly other CNS cell types release signals to inhibit microglial 
activation. When these signals are disrupted, e.g. by blocking the neuronal activity, microglial 
activation is triggered. Neurotransmitters are proposed to act as such signals. In addition, 
microglial activation can be induced by factors that are not normally present (viral or bacterial 
structures) or that show abnormal states (released intracellular components, protein 
aggregates). (Hanisch & Kettenmann 2007; Tambuyzer et al. 2009) 
2.1.5 DROSOPHILA NEURONS AND GLIA 
Similarily to mammals, the fruit fly Drosophila melanogaster has sensory neurons, interneurons 
and motor neurons. The neuronal structure is widely homologous among invertebrates and 
vertebrates, but differences do exist. . Vertebrate somatosensory neurons are derived from 
the CNS migratory precursors, are unipolar, and their somata locate to dorsal root ganglia 
(see section 2.2.1.4) from where their processes grow bidirectionally both towards the CNS 
and to innervate the periphery. The corresponding Drosophila neurons are bi- or multipolar, 
are born and located in the periphery and grow axons unidirectionally towards the CNS. In 
addition, vertebrate projection axons are myelinated and located in defined white matter 
tracts. Comparable axons in Drosophila locate to synaptic regions (neuropil) and individual 
axons lack glial ensheathment (Sanchez-Soriano et al. 2007). The structural arrangements of 
the Drosophila CNS are described in section 2.2.2. 
Drosophila neurons are usually smaller in size (see Fig. 1) and there are less of them: it has been 




while the human brain consists of 1011 neurons and mouse brain (C57Bl/6J strain) of 
75 000 000 neurons (Kandel et al. 2000; Williams 2000). Then number of glial cells is also 
lower: the Drosophila glia constitute 25% of the total brain cells while some estimates point 
that 65% of the mouse brain cells and 90% of the human brain cells are glial cells (Allen & 
Barres 2009). 
The functional classes of Drosophila glia resemble the vertebrate glial classes. Cortex glia, 
forming close contacts with neuronal cell bodies, the blood-brain barrier and tracheal 
elements, are very similar to vertebrate astrocytes. The Drosophila blood-brain barrier is 
formed by surface glia that tightly separate neurons and other glia from surrounding 
hemolymph. Neuropil glia resemble oligodendrocytes since they extend sheathlike 
membranes around target axons to provide an isolated space for neuronal action potentials 
and trophic support. Drosophila peripheral glia perform these functions in the periphery, 
similarly to the Schwann cells of vertebrates. Microglia do not appear to have a specific 
counterpart, but all glial types may perform immune cell-like functions. (Freeman & Doherty 
2006) 
2.1.6 DIFFERENTIATING BETWEEN THE CELLS OF THE CENTRAL 
NERVOUS SYSTEM 
Cell type and developmental stage-specific morphological and molecular characteristics can 
be utilized in identifying the cells of the nervous system. Having started this section with 
Santiago Ramón y Cajal, it is reasonable to end it by crediting Camillo Golgi, who shared the 
Nobel Prize in 1906 with Ramón y Cajal. Although wrong in his theory of a continuous, fluid 
exchanging neural network, his staining technique paved the way for Ramón y Cajal’s 
neuroanatomical discoveries. 
Histological staining is used for selectively highlighting cells and cellular components. In 
staining procedures, chemical reactions between chemicals and components within a tissue 
are utilized. Immunohistochemistry refers to a staining process where antibodies are used for 
specific recognition of molecules in the material of interest. Many of the molecular 
characteristics of certain cell types or the developmental status of the cell can be distinguished 
using the immunohistochemical procedures (see Table 6 in Methods, section 4.2.3). 
Apart from differentiating between cell types and cellular components, histological staining is 
utilized in the study of basic anatomy of the tissue, as well as examining the pathology, that is, 
regions of damaged tissue. The topics of functional anatomy and pathologies of the CNS are 




2.2 ANATOMICAL ORGANIZATION OF THE NERVOUS SYSTEM 
Estimated amount of glucose used by an adult human brain each day, expressed 
in M&Ms: 250. 
Harper's Index 
 
Neural pathways including a sensory input, a motor output and the information-integrating 
interneuron is highly conserved in all animal nervous systems. Very early in evolution, 
nervous systems were organized to form distinct modules performing different tasks. Early 
forms of centralized nervous systems consist of a longitudinal nerve cord and an anterior 
collection of nerve cells, a ganglia or a brain, at the cephalic end of the organism. This 
structure is found in flatworms (phylum Platyhelminthes). A more complex CNS is found in 
insects (phylum Arthropoda), brains of which are divided into regions performing different 
functions. During vertebrate nervous system evolution, the importance of the cerebral 
hemispheres and especially the cerebral cortex as the association centre becomes increasingly 
evident. (Lentz and Erulkar in Encyclopædia Britannica, www.britannica.com) 
The peripheral nervous system (PNS) lies outside of the CNS structures, and in vertebrates 
can be divided into somatic and autonomic peripheral nerves. Somatic division consists of the 
sensory neurons of dorsal root and cranial ganglia innervating the skin and musculature. 
Autonomic division controls the smooth muscles and the exocrine glands (Kandel et al. 2000). 
2.2.1 VERTEBRATE CENTRAL NERVOUS SYSTEM ORGANIZATION 
The main regions of the vertebrate CNS include the spinal cord, cerebellum, brain stem 
(comprised of medulla, pons and midbrain), diencephalon and cerebral hemispheres (Fig. 8). 
Spinal cord and brain stem function as relays between the CNS and PNS and contain 
pathways to and from the brain: sensory information is carried via ascending pathways, while 
the motor commands and regulation runs via descending pathways (see section 2.2.1.3). The 
thalamus (section 2.2.1.2) and hypothalamus are diencephalic structures. Hypothalamus 
regulates the autonomic nervous system and, through the pituitary, the hormonal balance of 
the body. The cerebral hemispheres consist of the cerebral cortex (section 2.2.1.1) and the 
underlying white matter, the basal ganglia, the hippocampus and the amygdala. The basal 
ganglia are formed by a group of interconnected nuclei, the striatum (composed of the 
caudate and putamen), the globus pallidus, the substantia nigra and the subthalamic nucleus 
and they contribute to movement regulation and cognition. The amygdala and hippocampus 
are part of the limbic system, which is suggested to process emotional reactions through 




involved in memory storage and spatial navigation. The cerebellum integrates motor, 
somatosensory and vestibular information in order to coordinate the movement. (Kandel et 
al. 2000) 
 
Figure 8. Mouse brain visualized in A) sagittal (cross-section from the midline) and B) coronal section 
(left hemisphere; the plane of cross-section is shown in A). Some major brain structures and white 
matter tracts are illustrated. Modified from Paxinos & Franklin 2001. 
2.2.1.1 Cerebral cortex 
Cerebral cortex is organized into distinct functional areas that have a characteristic pattern of 
connections. Most of the cortical surface in mouse is involved in sensory and motor 
information processing (Fig. 9A). Primary sensory cortical areas are the first areas in cortex to 
receive sensory information from the periphery while the primary motor cortex projects 
directly to the spinal cord. Higher order sensory cortex integrates information from the 
primary cortex, while higher order motor areas send processed information to primary motor 
cortex. (Kandel et al. 2000) 
Apart from the regional division, the cerebral cortex is organized into six layers (I-VI). Layer I 
below the pial surface is mainly composed of axons that run laterally and make contacts with 
the apical dendrites of the lower layer neurons. Layers II and III are composed of pyramidal 
neurons connecting to other cortical regions making association connections (within the 
hemisphere) and callosal projections (between hemispheres through the corpus callosum, see 
section 2.2.1.7). Layer IV neurons receive inputs from the thalamus and send information to 
projection neurons in layers III, V and VI. Layers V and VI comprise the major sites of 
outputs from the cortex, layer VI pyramidal neurons connecting to the thalamus and the large 
layer V pyramidals descending to the basal ganglia, brain stem and spinal cord (Fig. 10B, see 
also Fig. 3A). Depending on the cortical area, the size of the individual layers varies. Layer IV 
is thicker in primary sensory areas that receive vast subcortical input while motor cortex layer 





Figure 9. Regional and laminar organization of the cerebral cortex. A) The flattened mouse cerebral 
cortex shows the proportions of cortical regions, such as the primary sensory regions (somatosensory, 
S1, visual, V1 and auditory, Au) and primary motor cortex M1. The map is constructed from a full set 
of mouse coronal sections (see Fig. 8), the top representing the medioventral limit of the cortex (the 
corpus callossum) of each section. The vertical (y) axis represents distance from the medioventral 
margin measured around the surface of the cortex. Au, auditory (primary and secondary), Cg, 
cingulate, FrA, frontal association, Ins, insular, M1, primary motor, M2, secondary motor, Orb, 
orbital, Pir piriform (olfactory), Rhi, rhinal (entorhinal, ectorinal, perirhinal), S1, primary 
somatosensory, S2, secondary somatosensory, RS, retrosplenial, TeA, temporal association, V1, 
primary visual cortex, V2, secondary visual cortex. Modified from (Paxinos & Franklin 2001). B) 
Cerebral cortex is organized into layers, from which neurons project to distinct areas in the brain. 
Shown are the subcortical somatosensory projections from layers V and VI, and cortico-cortical 
connections from layers II and III, boh association connections within the same hemisphere or 
callosal projections to the other hemisphere. Dashed line presents the midline. VPL, ventral posterior 
lateral nucleus. Modified from Kandel et al. 2000. 
 
2.2.1.2 Thalamus 
The thalamus acts as the major relay system of the information passing to the cerebral cortex 
from other regions of the CNS or from the cerebral cortex itself. Distinct groups of neurons, 
nuclei, are separated based on the information that they transmit and the connections they 
make. All sensory information received by other areas of the CNS pass through the thalamus, 
with the exception of the olfactory afferents. The thalamus also relays motor information 




major inputs and projections are listed in Table 1. (Kandel et al. 2000; Sherman & Guillery 
2006) 
 
Table 1. Major thalamic nuclei are divided to specific relay nuclei that have well-defined inputs and 
connections to functionally specific cortical areas. Association nuclei receive most of their inputs from 





MAJOR OUTPUTS INFORMATION 
RELAYED 
Specific relay nuclei    
Ventral posterior Spinal cord / 
trigeminal nerve 
Somatosensory cortex Somatosensory 
Lateral geniculate Retina Visual cortex Visual 
Medial geniculate Cochlea Auditory cortex Auditory 
Ventral anterior /   
ventral lateral 
Spinal cord / Globus 
pallidus / cerebellum 
Motor cortex Motor 
Association nuclei    
Anterior group Hypothalamus Cingulate gyrus Limbic 
Medial dorsal Amygdala, 
hypothalamus 
Prefrontal cortex Limbic 
Lateral dorsal Hypothalamus, 
Cingulate gyrus 
Cingulate gyrus Emotional expression
Posterior group Spinal cord, cortical 
regions 
Somatosensory cortex 
(primary / secondary) 
Integration of 
sensory information 
Other    
Midline Reticular formation, 
hypothalamus 
Basal forebrain Limbic 
Intralaminar Reticular formation, 
spinal cord, cerebral 
cortex 
Basal ganglia and 
cortex 
Attention/arousal 
Reticular Cerebral cortex, 
thalamic nuclei 






2.2.1.3 General organization of the sensory and motor pathways 
Separate pathways carry visual, auditory, somatosensory and motor information and can be 
further divided into specialized pathways, e.g. the somatosensory pathway has distinct 
subsystems for sensations of pain and light touch. The sensory and motor neural pathways 
are topographically organized, that is, the spatial relationship of the peripheral 
receptive/output surface is preserved along the CNS relay systems (Kandel et al. 2000). Below 
is an introduction to the main pathways of somatosensory, visual and motor information 
carried to/from the cerebral cortex (Fig. 10). 
Somatosensory pathways 
Ascending somatosensory pathways deliver information from the receptors in the skin, joints 
and muscles of the trunk and limbs. The main two subdivisions, the medial lemniscal pathway 
and the anterolateral pathway (Fig. 10), mediate sensations of light touch and of pain and 
temperature, respectively. In both pathways the first order neuron soma is located in the 
dorsal root ganglion (DRG), from where it connects to the peripheral sensory receptor. The 
thalamocortical connection is generated by the third order neuron, which lies in the thalamus 
and projects its axon to layer IV of the primary somatosensory cortex. The pathways differ 
mainly in the location and behaviour of the second order neuron. In the medial lemniscal 
pathway, the soma of the second order neuron is in the nuclei of the medulla, from where its 
axon crosses the midline and projects to the thalamus. The tract from medulla to thalamus is 
called the medial lemniscus, from where the name of the pathway derives. The second order 
neuron of the anterolateral pathway is located in the dorsal horn of the spinal cord, from 
where it crosses the midline and ascends to synapse in the reticular formation, midbrain or 
thalamus. The thalamic nuclei innervated by the medial lemniscal pathway are the ventral 
posterior lateral (VPL) and posterior (Po). Apart from these two nuclei, the anterolateral 
pathway has intralaminar nuclei connections. (Kandel et al. 2000) 
Visual pathway 
In the retina, the light-sensitive photoreceptor cells synapse with bipolar cells, which then 
synapse to retinal ganglion cells. The axons of retinal ganglion cells project to the dorsal 
lateral geniculate nucleus (LGNd) in thalamus, axons from the nasal half of the retina 
crossing the midline in the optic chiasm. The pathway from LGNd to the primary visual 
cortex mediates the visual perception. A minor proportion of retinal connections are made to 
the midbrain and the superior colliculus, which control the papillary reflexes and eye 
movements, respectively. (Kandel et al. 2000) 
Corticospinal motor pathway 
The corticospinal motor pathway (or pyramidal tract, Fig. 10) is responsible for the execution 




layer V pyramidal neurons of the primary motor cortex. The rest of the axons originate from 
the supplementary and premotor areas. Regulatory inputs to the motor cortex arrive from the 
somatosensory and sensory association cortex, thalamus (ventral lateral nucleus), basal ganglia 
and the cerebellum. The motor cortical axons descend through the white matter structures of 
internal capsule and cerebral peduncle in the midbrain to pyramids of the medulla. Most of 
the axons cross the midline in the medulla and reach the lateral column of spinal cord and 
constitute the lateral corticospinal pathway. Some 10% cross only until they reach the anterior 
column of the spinal cord (anterior corticospinal pathway). In the ventral horn of the spinal 
cord, pyramidal axon synapses with the lower motor neuron. (Kandel et al. 2000) 
 
Figure 10. Somatosensory (medial lemniscal pathway on the left, anterolateral pathway on the right) 
and visual pathways carry information from the sensory receptors to the cortex. Motor pathway 
delivers motor commands from the cortex to the target muscles. Modified from Kandel et al. 2000; 
Squire et al. 2003. 
 
White matter components 
The axons in the described neural pathways project long distances and require efficient 
myelination for efficient conduction velocities. Bundles of these myelinated axons form the 
projection white matter tracts in CNS. The internal capsule is a white matter structure formed 




tract for motor information. In the brain stem, the medial lemniscal tract and cerebral 
peduncle/pyramidal tracts constitute the white matter tracts of somatosensory and motor 
information, respectively. Commissural tracts, such as the anterior and the posterior 
commissure and the largest fiber bundle in the brain, the corpus callosum, serve to connect 
the two cerebral hemispheres. 
2.2.2 INVERTEBRATE NERVOUS SYSTEM ORGANIZATION 
The Drosophila brain includes neural circuits for vision, olfaction, locomotion, and complex 
behaviors for mating, aggression, circadian rhythms as well as learning and memory. In 
comparison to vertebrate CNS, many aspects such as neurotransmitter systems are highly 
conserved. However, many adaptatations are notably different, such as the fly compound eye, 
introduced in the following section. 
2.2.2.1 Basic structure of the adult Drosophila visual system 
The entire adult Drosophila visual system consists of the retina, lamina, medulla, lobula, and 
lobula plate (Fig. 11 and Fig. 12). Genetic mutations or environmental conditions that alter 
the precise and repeating structure of the adult eye either in development or aging are 
relatively simply detected. This has been utilized in the study of human neurodegenerative 
disorders (see section 2.3.2.2). 
The Drosophila eye consists of approximately 800 ommatidia (Fig. 11) each containing a 
cluster of eight photoreceptor cells. Of these, six extend through the retina (R1–6), and the 
remaining two (R7, R8) locate to the upper and lower halves of each ommatidium. Each 
photoreceptor contains one rhabdomere, consisting of microvilli that function in light 
reception. The ommatidia are surrounded by primary and secondary pigment cells, which 
prevent the off-angle light from entering the photoreceptor system. Overlying the 
photoreceptors are the cone cells that secrete lens material and the pseudocone and 
transparent cornea for light focusing (Montell 1999; Wang & Montell 2007), Interactive Fly, 
http://www.sdbonline.org/fly/aimain/1aahome.htm.) 
From each ommatidium, eight photoreceptor axons project to distinct neuropils in the 
Drosophila brain. The R1–6 axons form synapses in the lamina, situated directly below the 
retina, whereas the R7–8 axons project through the lamina to the medulla. Lamina is linked to 
medulla and medulla to lobula by two successive chiasmata. Throughout the visual system, 
neurons are arranged as topographic arrays representing the arrangement of ommatidia. 
Lobula plate neurons connect the optic lobes of the two hemispheres and the lobula complex 
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The protocerebrum is a part of circuits controlling higher order behaviours such as the 
circuits mediating circadian behaviours. Mushroom bodies are structures within the 
protocerebrum and are involved in olfactory learning and memory. The central body complex 
comprises the ellipsoid body and the fan shaped body. These mediate aspects of learning, 
locomotion, and courtship and are associated with the protocerebrum. The antennal lobes are 
the first order neuropils in olfactory information processing. Antennal lobe neurons are 
innervated by the antennal sensory neurons and send projections to the mushroom bodies. 
Subesophageal ganglion neurons are involved in gustatory information processing. They 
receive input from taste neurons and mediate feeding behaviors. (Nichols 2006; Rein et al. 
2002), the FlyBrain project, http://flybrain.neurobio.arizona.edu/Flybrain/html/index.html.) 
 
Figure 12. Major structures of the adult Drosophila brain. Reprinted and modified from Nichols 2006, 




2.3 PATHOLOGICAL CONDITIONS OF THE NERVOUS SYSTEM 
De todas las reacciones posibles ante una injuria, la más hábil y económica es el 
silencio. 
Of all the possible reactions to an insult, the most effective and efficient one is 
silence. 
-Santiago Ramón y Cajal 
 
The American National Institute of Neurological Disorders and Stroke lists over 400 
neurological conditions including chronic pain, epilepsy and Alzheimer’s disease 
(http://www.ninds.nih.gov/disorders). Both common and rare forms of these pathological 
conditions cause disability and suffering for both affected individuals and those close to them. 
In the study of human disease, the etiology (the cause of the disease), pathogenesis 
(mechanism through which the disease develops), nature of the changes and the clinical 
outcome need to be determined. Causes including insults such as head injury or stroke, 
infections or inheritance may underlie a human neurological disorder. Inheritance contributes 
to a variety of developmental, degenerative and cerebrovascular diseases such as 
hydrocephalus, Parkinson’s disease or susceptibility to ischemic stroke. 
2.3.1 INHERITED DISORDERS OF THE CNS 
Inheritance of a disorder can manifest as a genetic predisposition (complex inheritance) or as 
monogenic (Mendelian) inheritance, where either one or two mutated copies of a gene can 
cause the disease. While monogenic diseases may be undervalued due to their rarity, they are 
valuable as models for complex, more common disease. For example, the rare inherited 
forms of Alzheimer’s and Parkinson disease have been crucial for dissecting the molecular 
background of these diseases. An interesting entity for genetic research has been the Finnish 
population. Due to the characteristics of the population history, a group of rare hereditary 
diseases are overrepresented in Finland and constitute the so-called Finnish disease heritage 
(Norio 2003b). Importantly, the establishment of the genetic basis of these 36 monogenic 
disorders has resulted in efficient molecular diagnosis but also provided novel avenues for 
basic research. 
2.3.2 ANIMAL MODELS OF HUMAN CNS DISORDERS  
Nobel prize winning research has been performed in experimental animals including the fruit 




Gallus gallus domesticus and mouse Mus musculus. Thus, these model systems have a long 
research tradition and are extremely well characterized. They can be studied along the whole 
spectrum of their development, even prior to the manifestation of disease symptoms, which 
is not normally possible in the humans. Experimental animals can be adjusted for specific 
needs of the study in question by selecting a suitable strain or characteristic, by manipulating 
the environmental factors and by genome manipulation techniques. 
In human disease modelling, there are two basic approaches for genetic manipulation. The 
forward genetics or phenotype-driven approach relies on screens for disease phenotypes after 
induced mutagenesis. Random mutations are generated by radiation, chemicals or by 
insertional mutagenesis, and the location of the mutation is mapped to find the cause for the 
interesting phenotype. In the reverse genetics or genotype-driven approach the known gene 
of interest is manipulated in order to study the phenotypic effects of the mutations. In 
addition, spontaneously occurring disease in larger animals, especially in dogs and sheep, have 
proven very advantageous in human disease modelling (Cooper 2010; Gagliardi & Bunnell 
2009; Tecott 2003). 
2.3.2.1 Mouse 
Perhaps the most widely used model system in human genetic disorder research is the mouse. 
Compared to humans, mice exhibit similar nervous system organization and similar 
behaviours. Even complex behaviours can be monitored in mice due to well-developed 
behavioural tests. Almost every human gene has a counterpart in the mouse genome, since 
97% of our genes are similar. In addition, mice are particularly suitable for genetic studies 
because of the availability of genetic manipulation techniques. Well-established methods exist 
to destroy a functional gene through removing or altering the gene sequence (knock-out 
mice), to mimic the effect of human mutation by producing a similar mutation in the mouse 
gene (knock-in mice) and to insert an extra gene into the mouse genome (transgenic mice). 
Apart from these genetically manipulated mice, the relatively long tradition of induced 
mutagenesis has resulted in mutations in genes relevant for human disease. (Hafezparast et al. 
2002; Harper 2010; Tecott 2003) 
2.3.2.2 Drosophila 
The fruit fly Drosophila melanogaster has been a powerful genetic tool for over one hundred 
years and during this time its genome, anatomy, physiology, behaviour and development have 
been characterized in detail. Its short reproduction cycle together with easy and low-cost 
maintenance make it an appealing laboratory organism. Through the analysis of naturally 
occurring and induced mutations a plethora of molecular pathways have been discovered and 
proven to be evolutionarily conserved. Especially the disease-causing genes appear to be 




Drosophila genome (Bier 2005). Established Drosophila models of neurodegenerative diseases 
suggest that mechanisms of neurodegeneration are well-conserved (Bilen & Bonini 2005; 
Muqit & Feany 2002). 
The power of Drosophila genetics is illustrated by the vast number of mutant lines available for 
research. The largest Drosophila strain resource, the Bloomington Drosophila Stock Center, lists 
nearly 50 000 stocks (http://flystocks.bio.indiana.edu/). Targeted gene deletions can be 
generated through the use of transposable element-based excision strategies (Ryder & Russell 
2003). Of particular importance is the ability to express/silence genes in a cell type-specific 
manner using the UAS-GAL4 system (Brand & Perrimon 1993). A Drosophila line carrying the 
yeast GAL4 transcription activator under the control of a cell or tissue-specific promoter is 
crossed with another line, where the gene of interest or an RNA interference (RNAi) 
construct is fused to the yeast upstream activator sequence (UAS). The controlled gene 
expression or gene silencing effect is observed in the resulting progeny. 
The possibility to access molecular pathways relevant to disease pathogenesis has made 
Drosophila disease modelling especially attractive. In genetic modifier screens an established 
disease phenotype is utilized to search for modifying effects by crossing the mutant to 
Drosophila lines carrying mutations in other genes. In this approach, second-site mutations or 
genome-wide RNAi libraries can be used for screening the enhancement or suppression of 
the original phenotype in an unbiased manner. The prerequisite for large-scale screening is a 
robust phenotype such as the rough-eye phenotype resulting from the degeneration or 
abnormal development of the adult compound eye structure. In candidate screening a 
selected set of mutation lines are used in a hypothesis-driven manner. (Marsh & Thompson 




2.4 NEURONAL CEROID LIPOFUSCINOSES 
Once I was like everybody else 
Once I was just like them 
Once I could do everything as the others and everything that I enjoyed 
Once I could do all that 
All that you can do when you can see 
Once no longer exists 
Once will never return 
Once will never ever return 
Once is no more 
-Ida Bernhardsson (1979-2009) 
 
In 1826, a Norwegian family of healthy parents had suffered a loss of their two eldest 
children from a disease manifesting with blindness, progressive mental deterioration, loss of 
speech and epilepsy. The remaining two children had a similar condition, which had started at 
the age of 6 years with deteriorating vision. The tragedy of this small town family was 
reported by Dr. Otto Christian Stengel, a physician at the Copper Mining Company of Røros 
(‘Beretning om et maerkeligt Sygdomstilfaelde hos fire Sødskende i Naerheden af Røraas’, 
Eyr et medicinsk Tidskrift, vol. 1, 1826, according to (Haltia 2006)). 
In 1896, the American neurologist Bernard Sachs described a disease termed ‘Familial 
Amaurotic Idiocy’ with rapid progression of visual loss and mental retardation combined with 
accumulation of lipid material within swollen neurons. During the following decades further 
studies by Drs Batten, Vogt, Spielmeyer, Jansky, Bielschowsky, Haltia and Santavuori, among 
others, lead to the distinction of the neuronal ceroid lipofuscinosis (NCLs) from the disease 
now known as Tay-Sachs disease. Today, NCLs are defined as ‘progressive degenerative 
diseases of the brain and, in most cases, the retina, in association with intracellular storage of 
material that is morphologically characterized as ceroid lipofuscin or similar’. Despite over 
100 years of research and the vast accumulation of knowledge on genes, proteins and 
pathways, there is no treatment to cure children with NCL disease. 
(http://www.ucl.ac.uk/ncl/, Haltia 2006) 
In the following sections, the NCL diseases are introduced focussing on the human disease 
symptoms and classification, together with the recent findings utilizing animal and cellular 




D are introduced more comprehensively (sections 2.4.4 and 2.4.5). The last section (2.4.8) 
focuses on phenomena that appear to be shared between different forms of NCL. 
2.4.1 HUMAN NCL DISEASE 
Collectively, the NCLs comprise the most common cause of progressive encephalopathies in 
children (Haltia 2006). Incidence is estimated to be 1:25 000-50 000 in the USA (according to 
The National Institute of Neurological Disorders and Stroke) and ranging between 1:25 000 
and 1:200 000 in European countries (e.g. Norway, Germany and Italy; Augestad & Flanders 
2006; Cardona & Rosati 1995; Claussen et al. 1992). The Finnish population is enriched with 
the infantile (CLN1), juvenile (CLN3), and late infantile (Finnish variant, CLN5) diseases and 
the progressive epilepsy with mental retardation (EPMR). Their respective incidences are 
1:14 000, 1:19 000, 1:59 000 and 1:176 000 (Norio 2003a). Mutation carrier frequencies reach 
1:60-1:70 in the whole population (CLN1, CLN3) but can be even higher than 1:50 in certain 
regions in Finland (CLN5, EPMR) (Kestila et al. 2010; Norio 2003a; Ranta et al. 1999; 
Savukoski et al. 1998). 
Symptoms of NCL disease include epileptic seizures, ataxia, mental and motor regression, 
myoclonus and/or visual failure. NCL diagnosis is made based on genetic or enzymatic tests 
from a blood, skin biopsy or saliva sample from the patient. Prerequisite for NCL diagnosis is 
the existence of intracellular storage material (section 2.4.2.2), which can be studied using 
electron microscopy on skin or rectal biopsies, or in lymphocytes of a blood sample. Light 
microscopy may show the vacuolated lymphocytes typical for the juvenile onset CLN3 
disease. Monitoring electroencephalogram (EEG), electroretinogram (ERG), measuring the 
visual and/or somatosensory evoked potentials (VEPs, SEPs) or performing 
neuroradiological analyses may assist the diagnosis of certain forms of NCL. 
(http://www.ucl.ac.uk/ncl/, Kousi et al. 2012) 
Currently, while a treatment to slow down or reverse the symptoms of NCL remains 
unavailable, the therapies aim to improve patients’ quality of life for as long as possible. 
Antiepileptic drugs are used to control the seizures. Palliative treatments include managing 
symptoms such as sleep disturbances, pain and feeding problems. According to the NCL 
subtype, symptom management may also target motor symptoms through antiparkinsonian 
drugs and/or physiotherapy and mental symptoms through combination therapy. 
(http://www.ucl.ac.uk/ncl/) 
2.4.2 CLASSIFICATION OF THE NCL DISORDERS 
The NCL diseases are classified based on molecular genetic findings, age of onset and the 




mutations have been reported in ten genes, PPT1, TPP1, CLN3, DNAJC5, CLN5, CLN6, 
MFSD8, CLN8, CTSD, GRN and ATP13A2 (Table 2). 
 
Table 2. The genetic basis of human NCL disorders. 
NCL 
subtype 








GROD Vesa et al. 1995 
CLN2 TPP1 / 
tripeptidyl-peptidase 1 
Late infancy  
(2-4 years) 
CL Sleat et al. 1997 
CLN3 CLN3 /CLN3 Juvenile  
(5-10 years) 
FP (CL, RL) The Int. Batten 
Dis. Consortium 
1995 
CLN4 DNAJC5 / DNAJ/HSP40 
homolog, subfamily C, member 5 
Adult GROD Noskova et al. 2011 
CLN5 CLN5 / CLN5 Late infancy  
(4-7 years) 
RL, CL, FP Savukoski et al. 
1998 
CLN6 CLN6 / CLN6 Late infancy  
(3-8 years) 
Adult 
RL, CL, FP 
 
FP, granular 
Gao et al. 2002;  
Wheeler et al. 2002 
Arsov et al. 2011 
CLN7 MFSD8 / major facilitator 
superfamily domain-containing 8 
Late infancy 
(2-7 years) 
RL, FP Siintola et al. 2007 
CLN8 CLN8 / CLN8 Late infancy  
(2-7 years) 
RL, FP, CL Ranta et al. 2004 





Ranta et al. 1999 
CLN10 CTSD / cathepsin D At birth 
(or juvenile) 
GROD Siintola et al. 2006; 
Steinfeld et al. 2006 
CLN11 GRN / granulin Adult FP# Smith et al. 2012 
CLN12 ATP13A2 / ATPase type 13A2 Juvenile lamellar* Bras et al. 2012 
Ultrastructural appearance of the storage material according to (Haltia 2006), except # according to 
Smith et al. 2012 and * according to (Tome et al. 1985). GROD, granular osmiophilic deposits; CL, 






The NCLs are primarily classified based on genetic findings. Most NCL subtypes have a 
predominant clinical picture (depicted in Table 2), e.g. mutations in the CLN3 gene 
predominately cause the juvenile onset disease. It is noteworthy, however, that most of the 
subtypes include variant phenotypes. Mutations in CLN8 lead to two clearly different NCL 
diseases, late infantile and protracted forms (section 2.4.4). Apart from this phenotypic 
divergence, there is phenotypic convergence among the NCLs. The subtypes of late infantile 
onset NCLs show similar clinical findings but may be caused by mutations in a number of 
NCL genes. (Kousi et al. 2012) 
2.4.2.2 Intracellular storage 
The key finding in NCL neuropathology is the intracellular autofluorescent storage (Fig. 13). 
The disease was named after the accumulating material, lipofuscin and ceroid. Lipofuscin 
relates to normal aging, while ceroid accumulation is seen in pathological conditions including 
disease, cell stress and malnutrition (Seehafer & Pearce 2006). Lipofuscin and ceroid are 
fluorescent and positive for periodic acid-Schiff (PAS), Sudan black B and Luxol fast blue 
(LFB) stains. Storage material is largely composed of protein, which in most NCLs is the 
subunit c of mitochondrial F1-F0-ATP synthase. In certain subtypes, mainly in infantile and 
congenital disease, the main protein components of the storage material are sphingolipid 
activator proteins (saposins) A and D. The ultrastructural appearance of the storage material 
is still important in the NCL classification and diagnosis. Electron microscopic examination 
reveals storage patterns including curvilinear (late infantile), fingerprint (juvenile), rectilinear 
















Figure 13. Storage material accumulation in NCL disease. The electron microscopic ultrastructural 
examination of the storage material shows A) granular osmiophilic deposits typical for CLN1 and 
CLN10, B) curvilinear profiles common in CLN2, C) fingerprint bodies of CLN3 and D) rectilinear 
profiles typical for most variant late infantile onset NCLs. In light microscopy, the accumulation of 
storage material can be visualized with E) immunostaining for subunit c of the mitochondrial ATP 
synthase (CLN5), F) Luxol fast blue, G) PAS and H) Sudan black B staining. Figures F-H are from 
CLN8 EPMR patient neurons. Magnifications A) x10000, B) x20000, C) x30000, D) x15000, E) x300, 
F-H) x1000. Adapted from Haltia 2003, reprinted with permission from Wolters Kluwer Health. 
 
2.4.3 NCL DISEASE IN ANIMALS 
NCL disease is not confined to humans but occurs widely in the animal kingdom. Disease has 
been described to affect various breeds of dogs, sheep and cattle but also affects domestic 
pig, goat, horse, cat and mouse. The naturally occurring models have been widely used in 
NCL research, especially prior to the development of techniques for the production of 
genetically modified mice. Two natural mouse models exist for the CLN8 and CLN6 disease 
(Cln8mnd and Cln6nclf, respectively) and both exhibit NCL pathology (Bronson et al. 1993; 
Bronson et al. 1998). The large animal models, especially the sheep model, have been widely 
studied (Cooper 2003). 
In addition to the naturally occurring animal disease, various experimental animals have been 
generated to study NCL disease. The most used model system has been the mouse. The 
mouse models show a neurodegenerative phenotype with autofluorescent storage and, with 
few exceptions, ultrastructural appearance and protein components of the storage similar to 




thalamocortical pathology (sections 2.4.7.4, 5.2.1 and 5.2.2) and premature death are common 
hallmarks of murine NCL. (Jalanko & Braulke 2009) 
Apart from mice, the NCL proteins CTSD, PPT1 and CLN3, which are well-conserved in 
evolution (Table 3), have been studied in Drosophila, C. elegans and unicellular yeasts 
Saccharomyces cerevisiae and Schizosaccharomyces pombe. Drosophila models that are deficient for 
Ppt1, Cln3 and cathepsin D (cathD) (see sections 2.4.5.4 and 5.1.2.2) show modest 
neurodegenerative phenotypes and/or reduced lifespans (Hickey et al. 2006; Myllykangas et al. 
2005; Tuxworth et al. 2011). The Ppt1 and cathD deficient Drosophila also show storage 
material accumulation (Hickey et al. 2006; Myllykangas et al. 2005; Tuxworth et al. 2011). No 
obvious NCL phenotype has been detected in C. elegans models for CLN1 and CLN3 (de 
Voer et al. 2005; Porter et al. 2005). The S. cerevisiae and S. pombe models have been succesfully 
used to study the CLN3 homologue Battenin (Btn1p) (Rakheja et al. 2008). 
2.4.4 CLN8 
Two types of human NCL disease are caused by mutations in the CLN8 gene. Late infantile 
onset CLN8 is clinically very similar to other late infantile variant NCLs while the progressive 
epilepsy with mental retardation (EPMR) exhibits a clinically atypical, protracted NCL 
subtype that so far has not been reported outside of Finland. Although these two diseases 
represent such different phenotypes, there appears to be no phenotype-genotype correlation 
in CLN8. 
Apart from the naturally occurring Cln8 mutant mouse, Cln8mnd, an NCL phenotype due to a 
missense mutation in the canine Cln8 gene has been reported in English Setter dogs (Katz et 
al. 2005). CLN8 is only conserved in vertebrates although a distantly homologous gene exists 
in the Drosophila genome. 
2.4.4.1 CLN8 disease, late infantile 
The late infantile onset CLN8 disease begins at 2-7 years of age with seizures, developmental 
regression and/or motor impairment. Subsequently, myoclonus, cognitive decline, ataxia and 
impairment of vision and speech appear. Disease progression is rapid and loss of ambulation 
follows approximately 2 years after disease onset. Most patients with CLN8 late infantile 
disease have been alive at the time of reporting, with ages up to 18 years, while one patient 
had died at the age of 10 years (Vantaggiato et al. 2009). The disease was first described in a 
subset of Turkish NCL patients but currently, patients with various origins have been 
diagnosed with CLN8 disease (Allen et al. 2011; Cannelli et al. 2006; Kousi et al. 2009; Kousi et 
al. 2012; Ranta et al. 2004; Reinhardt et al. 2010; Vantaggiato et al. 2009; Zelnik et al. 2007). 
Magnetic resonance imaging (MRI) has revealed cerebral and especially cerebellar atrophy, 




2011; Reinhardt et al. 2010; Striano et al. 2007; Topcu et al. 2004; Vantaggiato et al. 2009; 
Zelnik et al. 2007). In addition, hypointensity of the thalamus (Vantaggiato et al. 2009) as well 
as thinning of the corpus callosum (Striano et al. 2007) have been described. EEG of these 
patients is abnormal showing epileptiform activity. Visual impairment and blindness are 
accompanied by diminished/extinguished ERG and VEPs (Allen et al. 2011; Reinhardt et al. 
2010; Striano et al. 2007; Topcu et al. 2004; Vantaggiato et al. 2009; Zelnik et al. 2007). In 
electron microscopy, the neuronal storage material mainly consists of rectilinear and 
fingerprint profiles but additional curvilinear profiles and osmiophilic inclusions have been 
observed (Allen et al. 2011; Cannelli et al. 2006; Reinhardt et al. 2010; Vantaggiato et al. 2009; 
Zelnik et al. 2007). 
2.4.4.2 CLN8 disease, progressive epilepsy with mental retardation 
The EPMR disease, also called as Northern Epilepsy is characterized by childhood-onset 
epilepsy followed by mental deterioration and was described in families in Kainuu, 
northeastern Finland (Hirvasniemi et al. 1994). Development of the affected children is 
normal until 5-10 years of age. The disease starts with seizures which are generalized tonic-
clonic and, in some patients, complex partial seizures that first occur approximately once 
every 1-2 months. During puberty, seizure frequency increases to 1-2 seizures per week. 
Between 2-5 years after the onset of seizures, mental deterioration begins to manifest and 
progresses rapidly when seizures are most frequent. In adulthood, mental regression 
continues even when the seizures become more infrequent. Other symptoms include 
clumsiness in fine motor tasks and imbalance, dysphasic speech and behavioral problems. 
Visual acuity is decreased in approximately half of the patients but retinal degeneration has 
not been observed. All patients are moderate to profoundly retarded with IQs below 70 and 
need assistance in every day life in adulthood. Lifespan appears to be only slightly reduced, 
with death occurring after the fifth decade of life. (Hirvasniemi et al. 1994; Hirvasniemi et al. 
1995; Ranta & Lehesjoki 2000) 
Both magnetic resonance imaging (MRI) and computed tomography (CT) scans show 
progressive cerebellar and brain stem atrophy and, later in the disease, also cerebral atrophy 
(Hirvasniemi & Karumo 1994; Lauronen et al. 2001). EEG changes are mild until puberty, 
when slowing of the background activity, disappearance of the sleep patterns and scanty 
interictal epileptiform activity are obvious. VEPs were abnormal in some patients 
(Hirvasniemi et al. 1995). Neuropathological findings include the typical NCL storage material 
accumulation comprising of the mitochondrial ATP synthase subunit c and minor amounts of 
saposins A and D and amyloid  (Herva et al. 2000). Ultrastructurally, curvilinear profiles and 
granular appearance have been observed. However, the overall pathology is relatively mild 




and V neurons and the hippocampal CA2 sector show extensive storage and pathological 
changes, while other regions remain only mildly affected (Herva et al. 2000). 
2.4.4.3 CLN8 protein 
The CLN8 gene encodes a predicted 5-7 pass transmembrane protein that resides in the 
endoplasmic reticulum (ER) and partially in the ER-Golgi intermediate compartment 
(ERGIC). The protein has a C-terminal ER retention signal (lysine-lysine-arginine-proline, 
KKRP), the disruption of which causes the protein to be trapped in the Golgi apparatus 
(Lonka et al. 2000). None of the patient mutations studied so far disrupt the subcellular 
localization of CLN8 (Lonka et al. 2000; Vantaggiato et al. 2009). However, the pathological 
mouse mutation c.267–268insC (see section 2.4.4.4) was only found in the ER (Lonka et al. 
2000). In transfected primary neurons the CLN8 protein is localized to ER, yet in mouse 
brain the protein fractionates differently from markers of ER and ERGIC (Lonka et al. 2004). 
While some NCL proteins show axonal and/or synaptic localization in neurons, this appears 
not to be the case for CLN8 (Lonka et al. 2004). 
CLN8 is homologous to the yeast longevity assurance gene protein (Lag1p) and the 
translocating chain-associated membrane protein (TRAM) through the possession of a 
domain named TRAM-Lag1p-CLN8 or TLC (Winter & Ponting 2002). The human and 
mouse TLC domain family consists of six ceramide synthases (CerSs or longevity assurance, 
LASS proteins), three TRAMs, CLN8 and six other genes with unknown functions (Pewzner-
Jung et al. 2006). These multipass transmembrane proteins reside in ER and are well-
conserved in evolution (Levy & Futerman 2010). The ceramide synthase properties of TLC 
proteins were first discovered in yeast, where Lag1 and its paralogue Lac1 have been shown 
to be essential for the synthesis of very long fatty acid chain ceramides (Guillas et al. 2001). 
However, CLN8 is not likely to act as a ceramide synthase since the human CLN8 failed to 
rescue the yeast Lag1/Lac1 deficient phenotype, an opposite result to the human CerSs 
(Guillas et al. 2001; Guillas et al. 2003). Of the other TLC domain-containing proteins TRAM 
participates in the regulation of polypeptide translocation into the ER (Hegde et al. 1998; 
Voigt et al. 1996) and FAM57A (family with sequence similarity 57 member A) appears to be 
involved in amino acid transport (He et al. 2002). 
2.4.4.4 Motor neuron degeneration mouse Cln8mnd 
The c.267–268insC mutation in the murine Cln8 gene causes the NCL phenotype of the 
Cln8mnd mouse (Fig. 14). This spontaneous mutation appeared in an inbred substrain of 
C57Bl/6, B6.KB2/Rn (Messer & Flaherty 1986). Initial descriptions considered the motor 
neuron degeneration mouse, mnd, as a model for amyotrophic lateral sclerosis (ALS). These mice 
were shown to develop hindlimb weakness and ataxia between 5-11 months of age, leading to 




al. 1987). Yet the existence of autofluorescent storage inclusions consisting of mitochondrial 
ATP synthase subunit c with typical ultrastructural appearance indicated that these mice 
model the NCL disease (Bronson et al. 1993; Pardo et al. 1994). The mouse Cln8mnd mutation 
was reported alongside the human EPMR mutation (Ranta et al. 1999). 
Prior to the manifestation of motor deficits the Cln8mnd mice show behavioural abnormalities 
such as increased aggression. Decreased habituation and altered fear-conditioning response 
indicated that Cln8mnd mice display learning and memory related deficits (Bolivar et al. 2002). 
In addition, Cln8mnd mice show spontaneous spiking activity in EEG and are susceptible to 
kainic acid induced seizures (Melo et al. 2010). However, retinal degeneration is the first 
pathological change described in Cln8mnd mice. The thinning of retinal cell layers (Fig. 14D) 
and diminished ERG manifest already before one month of age. Retinal atrophy progresses 
to loss of the photoreceptor cell layer and degeneration of retinal ganglion cells by 3-4 
months of age. ERG is extinguished by 6 months of age. (Chang et al. 1994; Guarneri et al. 
2004; Messer et al. 1993).  
Many studies have focussed on the pathology of the Cln8mnd mouse spinal cord. Neuron loss 
concomitant with the onset of motor symptoms has been reported (Callahan et al. 1991; 
Gorio et al. 1999) while glial activation appears to precede these events (Mennini et al. 2004). 
In spinal cord, glutamate mediated excitotoxity has been proposed as a disease mechanism. 
The uptake of glutamate but not of GABA is decreased while the levels of ionotropic 
glutamate receptors are increased (Battaglioli et al. 1993; Mennini et al. 1998; Mennini et al. 
2002). Treatments with glutamate receptor antagonists have shown mild beneficial effects on 
the motor symptom onset (Elger et al. 2006; Mennini et al. 1999). 
Abnormalities in both excitatory and inhibitory neurotransmission have been proposed as 
disease mechanisms in the Cln8mnd brain. Increased glutamatergic transmission has been 
observed in the hippocampus (Bigini et al. 2012), while the hippocampus and cerebral cortex 
show loss of inhibitory GABAergic interneurons (Cooper et al. 1999). Glial activation possibly 
precedes these changes, which were observed in 9 month old mice, since the hippocampus 
has been shown to contain activated glia at 5 months of age (Melo et al. 2010). Upregulation 
of TNF, a microglial-secreted pro-inflammatory cytokine, and its receptors appears 
concomitantly or precedes the glial activation and may contribute to the neuroinflammation 
(Galizzi et al. 2011; Melo et al. 2010). In addition, TNF has been shown to be upregulated in 
Cln8mnd spinal cords (Ghezzi et al. 1998; Mennini et al. 2004). Oxidative stress and 
mitochondrial dysfunction have been suggested to contribute to the pathogenesis (Bertamini 
et al. 2002; Fujita et al. 1998; Kolikova et al. 2011) and recently, ER stress and unfolded protein 






Figure 14. Symptoms of the Cln8mnd mouse include A) motor deficits (shown is an attempt to walk 
uphill) and motor neuron pathology in B) dorsal motor nucleus and C) hypoglossal nucleus of spinal 
cord. D) Retinal cell layer thinning is observed early. GCL = ganglion cell layer; IPL = inner plexiform 
layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; Ph = 
photoreceptors; RPE = retinal pigment epithelium; CC = choriocapillaris. Magnifications B and C) 
x250, D) x400. Adapted from Messer and Flaherty, 1986 (A, B, C) and Chang et al. 1994; reprinted 




The NCL causative mutations in the CTSD gene were originally found in sheep, and only 
recently in humans (Siintola et al. 2006; Tyynela et al. 2000). Apart from NCL, CTSD has also 





2.4.5.1 CLN10 disease 
The earliest onset and most severe type of NCL disease is the congenital CLN10. Affected 
neonates die within hours to weeks after birth showing respiratory insufficiency and status 
epilepticus. Microcephaly, reduced brain size and the epileptic seizures have been suggested 
to start already during fetal development (Fritchie et al. 2009; Kousi et al. 2012; Sandbank 
1968; Siintola et al. 2006). To date, only 10 cases of congenital NCL have been reported 
(Kousi et al. 2012). In two of the patients, mutations in CTSD have been described, and loss 
of CTSD protein in brain tissue has been confirmed in three additional patients (Siintola et al. 
2006; Fritchie et al. 2009). Mutations in the CTSD gene have also been shown to cause 
juvenile onset NCL (Steinfeld et al. 2006). All CTSD mutations have been shown to result in 
abolished activity of CTSD enzyme (Fritchie et al. 2009; Kousi et al. 2012; Siintola et al. 2006; 
Steinfeld et al. 2006). 
2.4.5.2 CTSD protein 
The CTSD protein is a lysosomal aspartic protease. It mediates protein degradation, protease 
precursor activation and the processing of enzyme activators or inhibitors. CTSD has been 
suggested to process hormones, growth factors and antigens and to have a role in the 
regulation of apoptosis and plasma high density lipoprotein (HDL) cholesterol levels 
(reviewed in Benes et al. 2008). 
CTSD is synthesized as an inactive prepro-enzyme, which is posttranslationally processed to 
the active form during transport from ER via trans-Golgi network and late endosomes to 
lysosomes. The mature CTSD has a pH optimum of 3-4 and prefers peptide bonds flanked 
by hydrophobic amino acid residues. In vitro, its enzymatic activity can be specifically inhibited 
by pepstatin A, and it has been suggested to be activated by ceramide and prosaposin, the 
precursor protein for saposins A, B, C and D (Heinrich et al. 1999; Heinrich et al. 2000). 
Interestingly, in vitro substrates of CTSD include the saposins A-D, of which A and D 
accumulate in the human and sheep CLN10 disease (Benes et al. 2008; Gopalakrishnan et al. 
2004; Haidar et al. 2006). CTSD has been suggested to process amyloid precursor protein, 
apolipoprotein E (apoE) and tau, and thus be involved with Alzheimer’s disease. Non-
enzymatic functions have been suggested in cancer progression, since secreted pro-CTSD has 
mitogenic and growth factor-like properties on cancer cells (Benes et al. 2008; Liaudet-
Coopman et al. 2006). 
2.4.5.3 CLN10 disease in animals 
Mutations in CTSD were first shown to cause a congenital NCL in the White Swedish 
Landrace sheep. The newborn lambs presented with weakness, tremor and death within a few 




storage was detected. This disease was found to be due to a mutation in the Ctsd gene and an 
inactive CTSD enzyme. (Tyynela et al. 2000) 
Ctsd deficient (Ctsd–/–) mice were generated by disrupting the Ctsd open reading frame by the 
deletion of Ctsd exon 4 (Saftig et al. 1995). Ctsd–/– mice are apparently normal at birth but 
after two weeks severe neurodegenerative symptoms appear as epileptic seizures, tremor, 
muscle rigidity and blindness. In addition, the mice exhibit progressive pathology of the 
intestinal mucosa, loss of lymphoid cells of the spleen and thymus and death at the age of 25-
27 days in a state of anorexia. CTSD enzymatic activity is abolished but increased levels and 
activity of lysosomal enzymes including cathepsin B (CTSB) and TPP1 have been described. 
Ultrastructurally, the Ctsd–/– intracellular storage resembles the human storage (granular 
osmiophilic deposits), but the main protein component is the mitochondrial ATP synthase 
subunit c instead of saposins A and D that accumulate in humans and sheep. Neuropathology 
is characterized by neuronal loss and glial activation in cerebral cortex and thalamus. (Jalanko 
& Braulke 2009; Koike et al. 2000; Koike et al. 2003; Partanen et al. 2008; Saftig et al. 1995) 
In American bulldogs, a CTSD mutation and the consequently reduced enzymatic activity 
lead to young-adult onset NCL disease with ataxia, psychomotor retardation and premature 
death, but no loss of vision has been detected (Awano et al. 2006; Evans et al. 2005). Recently 
generated ctsd knockdown zebrafish shows disturbed eye and swim bladder development and 
reduced lifespan, but no lipofuscin storage was detected (Follo et al. 2011). 
2.4.5.4 Cathepsin D deficient Drosophila, cathD1 
The Drosophila cathepsin D (cathD; CG1548) encodes for a protein which is 50% identical and 
65% similar to the human CTSD. The cathD deficient Drosophila was generated through an 
imprecise excision of the transposable element EP2151 located 77bp upstream of the cathD 
open reading frame. In the resulting cathD1 mutant line more than 70% of the cathD coding 
sequence is lost and the mRNA expression of cathD is abolished. Development and lifespan 
are normal in cathD1 flies but they show modest late-onset neurodegeneration, observed 
through increased numbers of apoptotic nuclei in the 45-day-old cathD1 brain (Fig. 15). The 
typical NCL pathology was revealed by the progressive accumulation of autofluorescent and 
PAS/LFB positive storage material in neurons. Additionally, storage ultrastructure resembling 






Fig. 15. Cathepsin D deficiency in Drosophila. A&B) The 45 day old cathD deficient Drosophila (A) show 
increased cell death as compared to the age-matched control fly (B), especially in the visual areas of 
the brain, where arrowheads point to individual TUNEL positive neurons (r, retina; l, lamina; m, 
medulla). C) Quantification of cells positive for TUNEL (terminal deoxynucleotidyl transferase dUTP 
nick end labeling) staining. D) Age-dependent accumulation of autofluorescent storage material in 
cathD deficient Drosophila in the cortex of medulla. Scale bars in A&B 15 µm, in D, 5 µm. Df, 
deficiency. Adapted from Myllykangas et al. 2005, reprinted with permission from Elsevier. 
2.4.6 OTHER NCL DISEASES 
2.4.6.1 Infantile onset NCL 
The infantile onset CLN1 disease is caused by mutations in the palmitoyl-protein thioesterase 
1 gene, PPT1. Disease symptoms usually begin with hyperexcitability, muscular hypotonia and 
psychomotor regression at 10-18 months of age, followed by seizures and ataxia. Loss of 
vision, speech and ambulation manifest by the age of 3 years and death occurs between 6-15 
years of age (Santavuori et al. 2000). PPT1 encodes a soluble hydrolase that removes thioester-
linked fatty acid side chains from proteins. All of the reported PPT1 mutations result in 
reduced PPT1 enzyme activity (Kousi et al. 2012). 
2.4.6.2 Late infantile NCLs 
CLN2 disease, classic late infantile, is caused by mutations in the tripeptidyl-peptidase 1, 
TPP1, gene. The disease starts with seizures between the age of 2-4 years and progresses 
rapidly with visual deterioration, cognitive and motor decline, myoclonus, ataxia and speech 
decline. Premature death occurs between 6-15 years of age. The majority of the identified 




tripeptides from the N-terminus of small proteins. (Kousi et al. 2012; Santavuori et al. 2000; 
Sleat et al. 1997) 
CLN5 disease represents one of the variant forms of late infantile disease onset. Previously 
named Finnish variant late infantile disease, it begins with motor clumsiness, concentration 
disturbances and learning difficulties at 4-7 years of age, followed by mental and motor 
decline, myoclonus, epilepsy, ataxia and visual failure. Disease leads to loss of ambulation by 
the age of 9-13 years and death between 14-36 years of age. The CLN5 protein function is 
unknown. (Kousi et al. 2012; Santavuori et al. 2000; Savukoski et al. 1998) 
CLN6 disease, late infantile variant, is clinically highly similar to CLN2 late infantile disease, 
yet it shows a delayed onset and slower progression. Epileptic seizures and motor symptoms 
characterize the disease onset at 3-8 years of age. Mental decline, speech impairment, visual 
failure, myoclonus and ataxia follow. The disease leads to death in the third decade of life. To 
date, the function of CLN6 protein remains largely unknown. (Kousi et al. 2012; Mole et al. 
2005) 
CLN7 disease, variant late infantile, previously named as the Turkish variant late infantile 
disease, is caused by mutations in the major facilitator superfamily domain-containing 8, 
MFSD8, gene, encoding a lysosomal transporter (Siintola et al. 2007). To date, it has been 
described in patients of various origins with mostly family-specific mutations (Kousi et al. 
2012). The disease is phenotypically indistinguishable from the CLN8 late infantile disease 
described in section 2.4.4.1. 
2.4.6.3 Juvenile onset NCLs 
The most common form of NCL is CLN3 disease, classic juvenile. In pathological 
examination vacuolated lymphocytes in the peripheral blood are a characteristic finding. 
Disease manifests between 5-10 years of age. The progressive visual loss is tin most cases the 
presenting symptom, followed by epileptic seizures. During the course of disease children 
show progressive motor disabilities, ataxia and motor decline, and towards the end-stage of 
the disease behavioral abnormalities including hallucinations develop. Patients die 
prematurely at an average age of 20-30 years. The most prevalent CLN3 mutation is c.460-
280_677+382del967, resulting in a 1.02 kb deletion in the CLN3 mRNA. Function of CLN3 
is still largely unknown (1995; Kousi et al. 2012; Mole et al. 2005; Santavuori et al. 2000) 
A recent study described mutations in the ATP13A2 gene in a Belgian family with juvenile 
onset NCL, CLN12 (Bras et al. 2012). Mutations in this gene encoding a predicted lysosomal 
P5-type ATPase have previously been shown to cause juvenile Parkinsonism with dementia, 
Kufor-Rakeb syndrome (Ramirez et al. 2006). 
Another juvenile onset NCL disease, CLN9, was described as a separate subclass of NCLs 




date, the defective gene remains elusive. The four affected patients, with clinical phenotypes 
similar to the CLN3 classic juvenile disease, represent two families of Serbian and German 
origins. (Schulz et al. 2006) 
2.4.6.4 Adult onset NCLs 
Adult onset disease (ANCL) starts usually in the third decade of life and the patients die 
prematurely, approximately 12 years after disease onset. Visual loss is not typical but 
intracellular storage material accumulation is observed. The autosomal recessive and 
autosomal dominant adult onset NCLs present with very similar phenotypes (Haltia 2003). 
ANCL appears to be genetically very heterogenous. The original CLN number for ANCL, 
CLN4, has been designated to DNAJC5 encoding a cysteine string protein were identified in 
heterozygous state in a subset of families affected with autosomal dominant disease (Benitez 
et al. 2011; Noskova et al. 2011; Velinov et al. 2012). A subset of patients with the autosomal 
recessive disease has CLN6 mutations (Arsov et al. 2011). Homozygous mutations in granulin 
(GRN) were recently described in two siblings with autosomal recessive adult onset NCL, 
designated as CLN11. 
2.4.7 COMMON THEMES IN NCL PATHOGENESIS 
Although genetically heterogeneous, NCLs show largely similar symptoms and storage 
material accumulation. Thus, the mechanisms leading to disease onset have been 
hypothesized to be similar. This section briefly introduces phenomena that appear to be 
shared between different NCL subtypes. The focus is on neuropathological findings and on 
alterations in lipid metabolism. First, current knowledge on the different NCL proteins is 
summarized (section 2.4.7.1 and Table 3). 
2.4.7.1 Properties of NCL proteins 
Most NCL proteins localize to lysosomes, whereas the CLN6 and CLN8 proteins are 
localized to ER (Table 3). Of soluble lysosomal proteins, PPT1, TPP1 and CTSD are 
enzymes while the function of CLN5 is unknown. The functions of membrane-bound NCL 
proteins CLN3, CLN6 and CLN8 remain largely unknown. MFSD8 and ATP13A2 have 
hypothetical transporter and ATPase functions, respectively, and DNAJC5 regulates the 
ATPase activity of 70 kDa heat shock proteins (HSP70). Certain NCL proteins have a 
differential localization in neuronal cells in comparison to non-neuronal cells. For example, 
PPT1 localizes to lysosomes in non-neuronal cells, but in neurons and in brain the protein is 






Table 3. Functions and subcellular localization of NCL proteins. 
Defective protein 
/NCL subtype 
Function Localization Conservation 
enzymes/soluble    
CTSD/CLN10 aspartic protease lysosomal, secreted Eukaryota 
PPT1/CLN1 hydrolase, cleaves fatty 
acid side chains of 
proteins 









CLN5 unknown lysosomal, axonal Vertebrata 
GRN/CLN11 cell growth regulation secreted Vertebrata 
membrane proteins    








CLN6 unknown (lysosomal 
acidification?) 
ER Vertebrata 
MFSD8/CLN7 transporter lysosomal, late 
endosomal 
Vertebrata + Insecta 
CLN8 unknown (lipid 
regulation?) 
ER, ERGIC Vertebrata 
DNAJC5/CLN4 component of the 
synaptic chaperone 
synaptic vesicles Vertebrata + Insecta 
ATP13A2/CLN12 P5-type ATPase lysosomal Vertebrata 
Protein conservation based on HomoloGene, http://www.ncbi.nlm.nih.gov/homologene/, modified 
from Getty & Pearce 2011. Magnaporthe grisea = rice blast fungus. 
 
The molecular pathways that are disrupted in NCL disease are mostly unknown. NCL 
proteins have been suggested to operate in a common pathway (Jalanko & Braulke 2009). 
Indeed, many of the NCL proteins interact or modulate each other (Lyly et al. 2008; Persaud-




(Lyly et al. 2008). While different NCL proteins may also affect distinct pathways, these 
pathways ultimately converge to result in lysosomal dysfunction and storage. 
2.4.7.2 Abnormalities in the regulation of lipid metabolism 
Before the storage material in NCLs was determined to be composed mainly of protein 
(Palmer et al. 1986; Palmer et al. 1989; Tyynela et al. 1993), many biochemical studies focussed 
on lipids. More recently, interest towards the involvement of lipid metabolism dysregulation 
in NCL pathogenesis has re-emerged mostly through the use of large-scale lipid and gene 
expression analyses in cellular and animal models. Alterations in all major lipid classes, 
sphingolipids, phospholipids and cholesterol, have been reported (Jalanko et al. 2006). In 
addition, through bioinformatics approaches amino acid sequence similarities have indicated 
putative roles for the CLN8 and CLN3 proteins in lipid metabolism regulation (Narayan et al. 
2006; Winter & Ponting 2002). 
CLN8 
The TLC domain in the CNL8 sequence together with the subcellular localization of the 
protein indicate a role for CLN8 in lipid synthesis and/or transport of lipids between the ER 
and Golgi (Lonka et al. 2000; Winter & Ponting 2002). These hypotheses received further 
support through a large-scale lipid analysis of EPMR patient cerebral samples. The liquid 
chromatographic and mass spectrometric analyses revealed abnormal sphingo- and 
phospholipid levels depending on the disease stage (Hermansson et al. 2005). A patient with 
progressing disease showed reduced levels of ceramide, galactosyl- and lactosylceramide and 
sphingomyelin and the phospholipid plasmalogen. Accumulation of these lipids was observed 
in the advanced stage of the disease (Hermansson et al. 2005). CLN8 has been proposed to 
bind the sphingolipids GalC and ceramide in a lipid-protein binding assay performed in 
Cln8mnd mouse fibroblasts (Rusyn et al. 2008). In addition, mitochondria-associated ER-
membranes extracted from Cln8mnd mouse liver were shown to have abnormal properties and 
defects in enzymes involved in phospholipid synthesis and trafficking (Vance et al. 1997). 
CLN10/CTSD 
CTSD has also been linked to metabolism since it is proposed to participate in the regulation 
of lipid trafficking and degradation. CTSD is proposed to control intracellular cholesterol 
levels by regulating apolipoprotein A-I (apoA-I) mediated lipid efflux. The inhibition of 
CTSD in human macrophages is associated with reduced expression and mislocalization of 
ATP-binding casette transporter A1 (ABCA1), which mediates cholesterol and phospholipid 
efflux to apolipoproteins apoA-I and apoE (Haidar et al. 2006). As a result, accumulation of 
free cholesterol was observed in late endosomes/lysosomes (Haidar et al. 2006). Parallel 
findings have been reported in the Ctsd–/– mouse, with reduced ABCA1 protein levels and 




CTSD is involved in the proteolytic maturation of prosaposin into active saposins A, B, C 
and D, which are required for sphingolipid degradation (Gopalakrishnan et al. 2004). In 
Ctsd-/- the amount of prosaposin is increased, suggesting reduced amounts of active saposins 
(Jabs et al. 2008) while the overexpression of CTSD leads to increased amounts of both 
prosaposin and processed saposins (Haidar et al. 2006). Thus, impaired lipid degradation may 
cause the observed accumulation of bis(monoacylglycero)phosphate (BMP) and gangliosides 
GM2 and GM3 in the symptomatic Ctsd–/– mouse brains (Jabs et al. 2008) and the 
accumulation of glycosphingolipids when CTSD is inhibited in human macrophages (Haidar 
et al. 2006). 
Other NCLs 
Apart from CTSD, at least PPT1 and CLN5 appear to be involved in the regulation of 
cholesterol metabolism. In primary neurons extracted from the Ppt1Δex4 mouse, altered 
expression of cholesterol biosynthesis related genes was accompanied with upregulated 
cholesterol biosynthesis (Ahtiainen et al. 2007). However, total cholesterol was unchanged in 
these neurons and in Ppt1Δex4 mouse brain (Ahtiainen et al. 2007). Increased neuronal 
apolipoprotein uptake suggested disturbed apolipoprotein metabolism (Lyly et al. 2008). 
Decreased amounts of large high density lipoprotein (HDL) particles and phospholipid 
transfer protein (PLTP) were observed in Ppt1Δex4 serum (Lyly et al. 2008). CLN5 deficiency 
appears to present with an opposite effect, since increased levels of serum cholesterol and 
PLTP were observed in Cln5–/– mice, together with increased apoA-I mediated cholesterol 
efflux from macrophages (Schmiedt et al. 2012). The CLN6 pathogenesis may also relate to 
cholesterol homeostasis since the CLN6 deficient fibroblasts show alterations in cholesterol 
precursor related genes and accumulate free cholesterol in lysosomes (Teixeira et al. 2006). 
Many NCL proteins have been suggested to associate with lipid rafts, the sphingolipid and 
cholesterol rich plasma membrane microdomains proposed to be involved in membrane 
trafficking and signal transduction (Simons & Ikonen 1997). PPT1 (Goswami et al. 2005) and 
CLN3 (Hobert & Dawson 2007; Rakheja et al. 2004; Rusyn et al. 2008) have been proposed to 
regulate lipid raft properties such as glycosphingolipid content and transport. 
Glycosphingolipid transport defects were also observed in Cln5–/– mouse macrophages and 
fibroblasts (Schmiedt et al. 2012). Similarly with the Ctsd–/– mouse, accumulation of 
gangliosides has been observed in CLN6 patient fibroblasts and the mouse model (Jabs et al. 
2008; Teixeira et al. 2006). CLN9, although the gene itself remains uncharacterized, has been 
suggested to act as a regulator of dihydroceramide synthase based on the properties of patient 
fibroblasts (Schulz et al. 2006). 
The phospholipid species distribution has been shown to be altered in human CLN1 brain 
samples (Kakela et al. 2003) while only minor changes in phospholipid composition were 




et al. 2003). The levels of CLN3 and the phospolipid BMP appear to correlate, since BMP is 
reduced in patient fibroblasts and increased when CLN3 is overexpressed (Hobert & Dawson 
2007). In addition, the yeast CLN3 homologue BTN1 has been shown to regulate 
phospholipid levels and their intracellular transport (Padilla-Lopez et al. 2012). 
2.4.7.3 Selective neuropathological changes especially in thalamocortical pathways 
NCL neuropathology is characterized by neuron loss that specifically affects distinct regions 
and neuron types of the brain. In general, neuron loss is preceded by gradual reactive changes 
in astrocytes and microglia. While most of these studies have been conducted using animal 
models, largely similar observations have been made in human post-mortem material. 
(Cooper et al. 2006; Cooper 2010) 
Neuron types that appear selectively vulnerable in NCL pathology are inhibitory interneurons 
and thalamocortical relay neurons. The pathology of hippocampal and cortical GABAergic 
interneurons has been described in CLN1, CLN3, CLN5 and CLN8 mouse models and in 
CLN6 sheep (Bible et al. 2004; Cooper et al. 1999; Jalanko et al. 2005; Kopra et al. 2004; 
Oswald et al. 2001; Oswald et al. 2008; Pontikis et al. 2005). Particular effect of NCL disease is 
shown in the thalamocortical and corticothalamic pathways. Thalamic relay neurons appear to 
be lost prior to their projection sites in the animal models of most NCL subtypes (Kielar et al. 
2007; Partanen et al. 2008; Pontikis et al. 2005; von Schantz et al. 2009; Weimer et al. 2006). 
This sequence is reversed in the Cln5–/– mouse (von Schantz et al. 2009). Especially the 
sensory thalamocortical pathways are affected early in disease progression (Bible et al. 2004; 
Kielar et al. 2007; Oswald et al. 2005; Partanen et al. 2008; von Schantz et al. 2009). 
The activation of astrocytes and microglia is connected to NCL disease pathogenesis. 
Astrocytosis has been shown to precede neuron loss in the cerebral cortex, hippocampus, 
thalamus and cerebellum (Kielar et al. 2007; Macauley et al. 2009; Partanen et al. 2008; Pontikis 
et al. 2004; Pontikis et al. 2005; von Schantz et al. 2009). In many NCL subtypes, microglial 
activation follows astrocytosis but early microglial activation is observed in the CLN6 sheep 
(Kay et al. 2006; Oswald et al. 2005) and in Cln5–/– mouse (Schmiedt et al. 2012). It is not 
known whether glial response accelerates neurodegeneration or whether it has 
neuroprotective effects. A recent study in the CLN1 mouse model addressed this question: 
astrocyte activation was genetically attenuated (Ppt1–/–, Gfap–/–, Vimentin–/–), resulting in 
earlier appearing and more rapidly progressing pathology (Macauley et al. 2011). This indicates 




3 AIMS OF THE STUDY 
This study aimed to determine molecular events contributing to disease progression in the 
neuronal ceroid lipofuscinosis CLN8 and CLN10. Specific aims were 
 
1) to investigate the genetic interactions and pathways of cathepsin D using the 
cathepsin D deficient Drosophila model for CLN10 disease, cathD1 
2) to characterize the neuropathology and spatio-temporal disease progression in 
the CLN8 disease model, Cln8mnd mouse, by 
 2a) determining the sequence of pathological events in the Cln8mnd mouse 
thalamocortical pathways, 
 2b) defining the role of white matter defects in the Cln8mnd mouse, implicated 






4 MATERIALS AND METHODS 
By three methods we may learn wisdom: First, by reflection, which is noblest; 




In this chapter, materials and methods utilized in Studies I, II and III are described. Roman 
numeral indicating the study in question is included in the title of each section. 
4.1 MATERIALS 
4.1.1 DROSOPHILA STRAINS, HUSBANDRY AND CROSSES (I) 
The Drosophila strains used in this study were obtained from the Bloomington Drosophila Stock 
Center at Indiana University, The Exelixis Collection at the Harvard Medical School and 
individual research groups (for references, see Table 4). The overexpression lines for cathepsin 
B (cathB) and cathD were generated as described in I. The cathD1 genotype was verified with 
two polymerase chain reaction (PCR) setups, one with primers spanning the deletion (product 
size depends on the cathD genotype, see I) and one with primers within the deleted sequence 
of cathD1 (no product when cathD1 in homozygous state). Primers used for the latter PCR 
were F: AAC ATA GAA ATC AAA ATG CAG AAG G and R: GTT CTT GGT GTA 
GGT CTT CGA CTT (F and R for forward and reverse, respectively). 
The stocks of the Drosophila strains were maintained at room temperature whereas crosses and 
aging of the flies were performed at 25°C. Flies were raised on standard media including agar, 











Table 4. Drosophila strains utilized in this study. 
Gene name Human homolog Fly line Genotype 
cathD cathepsin D (CTSD) Myllykangas et al. 
2005 
cathD1/cathD1 
  I elav-GAL4/+; cathD1; UAS-
cathD 
Ceramidase (CDase) non-lysosomal ceramidase 
(ASAH2) 
Acharya et al. 2003 elav-GAL4/+; cathD1; UAS-
CDase/+ 
CG10992 (cathB) cathepsin B (CTSB) Bourbon et al. 2002 CG10992PG148/+; cathD1 
  I elav-GAL4/+; cathD1; UAS-
cathB/+ 
CG17841 - 
(TLC protein domain containing) 
Bourbon et al. 2002 CG17841PL94/+; cathD1 
HMG Coenzyme A 
reductase (Hmgcr) 
HMG-CoA reductase (HMGCR) Tschape et al. 2002 elav-GAL4/+; cathD1; UAS-
Clb/+ 
Heat shock protein cognate 3 
(Hsc70-3) 
heat shock 70kDa protein 5 
(HSPA5) 
Bloomington #11815 Hsc70-3G0102/+; cathD1 
Heat shock protein cognate 4 
(Hsc70-4) 
heat shock 70kDa protein 8 
(HSPA8) 
Bloomington #10286 cathD1; Hsc70-4L3929/+ 
Saposin-related (Sap-r) prosaposin (PSAP) Exelixis Collection cathD1; Sap-re01294 
cathD1; Sap-re01294/+ 
schlank (lag1) ceramide synthase 5 (CERS5) Bloomington #11665 lag1G0061/+; cathD1 
shibire (shi) dynamin 1 (DNM1) Bloomington #7068 shi1/+; cathD1 
SNF4/AMP-activated protein 
kinase gamma subunit (loe) 
protein kinase, AMP-activated, 
gamma 2 (PRKAG2) 
Tschape et al. 2002 cathD1; SNF4loe/+ 
elav-GAL4/+; cathD1; UAS-
loeI/+ 
Superoxide dismutase (Sod) superoxide dismutase 1, soluble 
(SOD1) 
Bloomington #4015 cathD1; Sodn1/+ 
swiss cheese (sws) patatin-like phospholipase 
domain containing 7 (PNPLA7) 
Exelixis Collection swsd07605/+; cathD1 
Target of rapamycin (Tor) mechanistic target of rapamycin 
(MTOR) 
Bloomington #7012 elav-GAL4/+; cathD1; UAS-
TorWT/+ 




thioredoxin reductase 2 
(TXNRD2) 




Table 4 continued. Drosophila nomenclature used here is based on FlyBase (www.flybase.org). elav, 
embryonic lethal abnormal vision. 
4.1.2 Cln8mnd MOUSE (II, III) 
Mouse strain B6.KB2-Cln8mnd/MsrJ was obtained from the Jackson Laboratory, backcrossed 
to C57Bl/6JolaHsd and C57Bl/6JRccHsd and congenity verified as described in II and III. 
Homozygous Cln8mnd/Cln8mnd mice (Cln8mnd) and their wild-type (wt) littermates were used. 
The experiments were performed in accordance with good practice of handling laboratory 
animals and using protocols approved by the ethical boards for animal experimentation of the 
National Public Health Institute and University of Helsinki, as well as State Provincial Offices 
of Finland (approval numbers ESLH-2008-00840/Ym-23, STH114A, ESLH-2008-
10286/Ym-23, STH967A, ESAVI-2010-04382/Ym-23 and KEK09-061). Mice were housed 
at the Center for Laboratory Animals, University of Helsinki. 
4.1.3 MOUSE PRIMARY CELL CULTURES (III) 
Mouse primary neurons, astrocytes and oligodendrocytes were produced as described in III, 
modified from (Heinonen et al. 2000; Pedraza et al. 2008). Shortly, the hippocampal / cortical 
tissue was dissected from mouse embryos of the embryonic day (E) 15.5-17.5 and triturated 
to one-cell-stage using trypsin (Sigma). For neuron cultures, cells were plated in Neurobasal® 
Medium supplemented with 1x B-27, 1x GlutaMAX™-I, penicillin (50 U/ml) and 
streptomycin (50 µg/ml) (all from Gibco). Primary astrocytes were dissected similarly and 
cultured in DMEM (Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L Glucose, 
BioWhittaker®) with 10% fetal calf serum (FCS; Promo Cell®), 1x GlutaMAX™-I and 
antibiotics. Oligodendrocytes were differentiated in DMEM containing 1x B-27 and 3% FCS 
after the neural progenitor / oligodendrocyte progenitor cell expansion (according to Pedraza 





Description of the key techniques utilized is presented in this section. Full list of methods is 
presented in Table 5. 
Table 5. Methods used in this study. 
Method Used in 
DNA extraction I 
Drosophila crosses I 
Molecular cloning I 
Polymerase chain reaction I 
Histologic processing I, II, III 
Light microscopy I, II, III 
(Immuno)histochemistry I, II, III 
Quantitative PCR I, III 
Reverse transcription I, III 
RNA extraction I, III 
Stereology II, III 
Statistical analysis II, III 
Cell culture III 
Cell proliferation assay III 
Enzyme activity measurement III 
Fractional anisotropy III 
Immunocytochemistry III 
Lipid mass spectrometry III 
Magnetic resonance imaging III 
Transmission electron microscopy III 
Myelin g ratio measurements III 
Western blotting III 
Nerve conduction velocity measurements Unpublished 
  
4.2.1 HISTOLOGICAL PROCESSING (I, II, III) 
Adult Drosophila were fixed in 4% formalin at least overnight in +8C at 1, 10, 20, 30 and 45 
days of age. After fixation, flies were transferred to 70% ethanol and embedded in paraffin 




University of Helsinki). Flies were decapitated and heads embedded in paraffin blocks. 
Coronal sections of 4 µm thickness were cut and transferred to SuperFrost Plus glass slides 
(Menzel-Gläser) and dried +37C overnight. 
The Cln8mnd mice and their littermate controls were sacrificed at 1, 3, 5 and 8 months of age, 
when their brains were dissected and fixed in 4% paraformaldehyde in phosphate buffered 
saline (PBS). The cryoprotection and cryosectioning were performed as described in II. The 
mouse primary cell cultures were fixed for 15 min in 4% paraformaldehyde solution and 
stored in PBS +4C until stained. 
4.2.2 HISTOLOGY AND IMMUNOHISTOCHEMISTRY (I, II, III) 
The staining methods utilized in this study are listed in Table 6. For Drosophila adult heads 
standard haematoxylin-eosin staining was used. Briefly, it consisted of paraffin elimination 
through a graded ethanol series, followed by standard haematoxylin-eosin staining and graded 
ethanol series to xylene. The phenotypic enhancements were estimated in these sections 
under the 40x objective. Compared to the cathD1 phenotype, enhancement was considered 
when more than 10 times vacuoles were present and weak enhancement, if more than 2 times 
but less than 10 times vacuoles were present. 
Mouse brain sections for stereology were mounted onto gelatin-chrome alumin coated glass 
slides and air-dried. The slides were incubated for 30 minutes at 60C in Nissl stain solution 
consisting of 0.05% Cresyl fast violet (VWR)/0.05% acetic acid, rinsed in distilled water, 
differentiated through a graded series of alcohols and xylene (VWR) and coverslipped with 
DPX (VWR). In addition, immunohistochemical stainings were performed to detect GFAP, 
CD68, NeuN, MBP and MOG (II, III). Mouse primary cells were stained as described in III. 
Details of the antibodies used are given in Table 6. 
 
Table 6. Basis of the histological stains and antibodies used for immunohistology, 
immunocytochemistry and the immunostaining of protein blots. Antibody dilutions used in 
experiments are shown here; protocols in full are given in the original publications. 
Staining Basis Used in 
Histological stains  
Haematoxylin-
Eosin 
Hematoxylin is a basic dye staining nuclei and rough ER due to its affinity to 




Stains cell nuclei and rough ER nucleic acids due to its affinity to nucleic acids. II, III 




Table 6 continued. 
Staining Basis Used in 
Immunohistochemistry  
GFAP Glial fibrillary acidic protein, an astrocytic intermediate filament. Staining is 
regarded as highly specific for reactive astrocytes (Sofroniew & Vinters 2010). 
rabbit anti-GFAP, 1:4000, Z0334, DAKO 
II 
CD68 Cluster of differentiation 68 or macrosialin is a member of the lysosomal-
associated membrane protein (LAMP) family expressed by macrophages 
(Sanchez-Guajardo et al. 2010). 
rat anti-CD68, 1:2000, MCA1957, AbD Serotec 
II 
NeuN Neuronal Nuclei, recognizes the neuronal specific protein RBFOX3 (RNA 
binding protein, fox-1 homolog (C. elegans) 3) (Kim et al. 2009). 
mouse anti-NeuN, 1:1000, MAB377, Millipore 
II 
MBP Myelin basic protein is a structural component of myelin and a marker for 
mature oligodendrocytes (Bradl & Lassmann 2010). 
rat anti-MBP, 1:500, MAB386, Millipore 
III 
MOG Myelin and oligodendrocyte glycoprotein is a marker of differentiated 
oligodendrocytes (Bradl & Lassmann 2010). 
rat anti-MOG, 1:200, MAB2439, R&D Systems 
III 
Immunocytochemistry  
MBP rat-anti-MBP 1:100, see above. III 
GalC Galactoceramide is a myelin-enriched lipid and a marker for differentiating pre-
oligodendrocyte and mature oligodendrocytes (Bradl & Lassmann 2010). 
anti-GalC 1:100, MAB142, Millipore 
III 
A2B5 Stains gangliosides and serves as a marker for oligodendrocyte progenitors and 
oligodendrocytes in their early-development (Baumann & Pham-Dinh 2001). 
anti-A2B5 1:200, MAB312, Millipore 
III 
Olig2 Transcription factor of the oligodendrocytic lineage, which is expressed 
throughout the oligodendrocyte development but higher in oligodendrocyte 
progenitors (Bradl & Lassmann 2010). 
anti-Olig2 1:500, AB9610, Millipore 
III 
Western blotting  
MBP rat anti-MBP, 1:250, see above III 
PLP Proteolipid-protein is a marker for differentiated oligodendrocytes (Bradl & 
Lassmann 2010). 
mouse anti-PLP, 1:1000, ab9311, Abcam 
III 
MOG rabbit anti-MOG, 1:500, 12690-1-AP, ProteinTech Group III 
NG2 Chondroitin sulphate proteoglycan 4 is a marker for oligodendrocyte 
progenitors (Bradl & Lassmann 2010). 





4.2.3 LIGHT MICROSCOPY (I, II, III) 
Immunostained mouse brain sections and adult Drosophila sections were observed and imaged 
using the using Zeiss Axioplan2 microscope, AxioCam HRc camera and AxioVision Release 
4.6 software (Carl Zeiss). Images were processed (brightness/contrast, scaling) using the 
Adobe Photoshop CS4 software (Adobe Systems). Confocal microscope (LSM 510 Meta, 
Zeiss Inc.) was used for imaging the immunofluorescently stained oligodendrocytes as 
described in III. 
4.2.4 STEREOLOGY (II, III) 
A stereological optical dissector was used for the analysis of the neuron number and a 
Cavalieri estimator for the volumetric analyses. Analysis included 4-6 animals per genotype 
and age. From the one in six series of the Nissl-stained sections the appropriate anatomical 
region was defined using the Paxinos and Franklin mouse brain atlas (Paxinos & Franklin 
2001) and performed using StereoInvestigator program (MBF Bioscience) as described in II 
and III. All analyses were performed with no prior knowledge of the genotype of the sample. 
4.2.5 ELECTRON MICROSCOPY, G RATIO ANALYSIS (III) 
For electron microscopy sample preparation, 1 and 4 month old mice were perfusion fixed 
with 4% PFA, the brains dissected and post-fixed in 6% glutaraldehyde solution overnight. 
Samples were cut to appropriate size (approximately 1mm3) selecting the regions of brain 
stem and the frontal region of corpus callosum and transferred to phosphate buffer, pH 7.4. 
Sectioning and staining was provided as a service of the Institute of Biotechnology Electron 
Microscopy Unit, University of Helsinki. Under the electron microscope a set of 
representative pictures was taken choosing locations of bundles of myelinated axons. For g 
ratio analyses these pictures were analysed using the Fiji image analysis package by measuring 
the length of individual axon diameters versus corresponding fiber diameters as described in 
III. 
4.2.6 MAGNETIC RESONANCE IMAGING, FRACTIONAL ANISOTROPY (III) 
MRI was performed as described in detail in III resulting in data sets with and without 
diffusion weighting (diffusion tensor imaging, DTI). Volumetry for corpus callosum and 
internal capsule and the corpus callosum thickness were measured from the anatomical 
images without diffusion weighting. Diffusion tensor images were used from fractional 
anisotropy analyses. The region of interest (ROI) analysis for white matter structures is 
explained in III. In addition, a hypothesis free analysis method, track based spatial stastistics, 




4.2.7 LIPID ANALYSES, ENZYME ACTIVITY MEASUREMENTS (III) 
Mouse brain samples were homogenized with chloroform/methanol (9:1) and the lipids 
extracted as described in (Folch et al. 1957). Quantification of sphingolipids was performed 
using a liquid chromatography / mass spectrometry based analysis, as previously described 
for human EPMR samples (Hermansson et al. 2005). Free cholesterol was quantitated 
according to (Gamble et al. 1978). 
For CGT enzyme activity measurements, mouse cerebral cortices were homogenized and 
protein concentrations determined to adjust them to 4 mg/ml (Zoller et al. 2005). Samples 
were incubated with the radioactive substrate, [14C]-UDP-galactose (I). Radioactivity 
detection was performed as described in (Zoller et al. 2005). 
4.2.8 WESTERN IMMUNOBLOTTING (III) 
Mouse brain samples were lysed and prepared for polyacrylamide gel electrophoresis as 
described in III. Proteins were blotted and detected using immunostaining and either 
enhanced chemiluminiscence or infrared imaging based methods as described in III. 
4.2.9 QUANTITATIVE PCR (I, III) 
Total RNA was extracted from cells and tissues using the Qiagen RNeasy mini kit (Qiagen). 
Complementary DNA (cDNA) synthesis was performed using Moloney murine leukemia 
virus (MMLV) reverse transcriptase and random hexamers as primers (Promega) using a 
standard protocol (Joensuu et al. 2008). Real-time reverse transcriptase PCR was performed 
using commercial, mRNA specific primer/probe assays (III) or designed by the 
PrimerExpress software (Applied Biosystems). The Drosophila assays designed for cathD, 
cathepsin B (cathB) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were as follows: Gapdh (F - 
AGC GCT GGT GCC GAA TAC, R - AGT GAG TGG ATG CCT TGT CGA T, probe - 
TGG AGT CCA CTG GCG TGT TCA CCA), cathB (F - TGC CGT GGA AGC CAT GT, 
R - CCG AAA AGT GGA AAT TCA CCT T, probe - CGA TCG CGT GTG CAT CCA 
TTC C), cathD (F - CAT CGG TGG TCA GTA TGT GGT T, R - CGC CCA GCA CAA 
ACT TGA TT, probe - CTT GCG ATC TCA TTC CCC AAT TGC C). Probes contained 6-
carboxyfluorescein (FAM) and tetramethylrhodamine (TAMRA) fluorophores at their 5’ and 
3’ ends, respectively. 
4.2.10 NERVE CONDUCTION MEASUREMENTS (UNPUBLISHED) 
One and 4 month old mice (n=6 per genotype per age group) were analysed for peripheral 




& Stoffel 2004). The mice were anesthetized using 50 mg/kg sodium pentobarbital 
(Mebunat®, Orion) by intraperitoneal injection. During measurements, the mice were 
spontaneously breathing and their body temperature was maintained within the physiological 
range. To limit movement-related artefacts the hind limbs were fixed to a styrofoam base 
with thin needles. 
For recordings of motor evoked potentials a concentric bipolar electrode (Rhodes NE-100) 
was inserted into the hind paw muscle. The signal was amplified and filtered using standard 
techniques. Stimulation electrodes (27G needles) were placed into 1) the lumbar spine, close 
to the emergence of the sciatic nerve roots, and 2) the metatarsal right below the calcaneum. 
The distance between these sites was measured with a calliper. The electrical stimuli were 
generated by a constant current stimulator (PSIU6 and Grass S88, Grass Instruments). For 
stimulation, 0.2 ms impulses with an intensity of 1.5x the motor threshold were used at a rate 
of 1 Hz. 
At least 20 motor evoked potentials were acquired for each analysis. Data sampling was 
performed with a computer connected to a CED Micro 1401 interface and using Spike 2 
software (Cambridge Electronic Design). 
4.2.11 STATISTICAL ANALYSIS (II, III) 
Results were statistically tested by Student’s t-test, two-way analysis of variance (ANOVA) 
with Bonferroni post-hoc test, or Mann-Whitney U-test, when applicable, using Microsoft 





5 RESULTS AND DISCUSSION 
Who could have guessed that the lowly fruit fly might hold the key for decoding 
heredity? Or that the mouse might one day disclose astonishing evolutionary 
secrets? 
-‘Of Flies, Mice, and Men’ by François Jacob, from the book description, 
Amazon.com 
 
5.1 MODULATORS OF CLN10 NEUROPATHOLOGY IN 
DROSOPHILA 
The cathD1 Drosophila model for CLN10 disease is characterized by modest neurodegeneration 
and autofluorescent storage (Myllykangas et al. 2005). In this study, late-onset retinal 
degeneration was observed. In order to find modulators of the cathD1 phenotype and possible 
pathways relevant for CLN10 disease, the cathD1 retinal phenotype was utilized for 
hypothesis-based candidate modifier screening. 
5.1.1 RETINAL PATHOLOGY OF cathD1 DROSOPHILA (I) 
The neuronal apoptosis in aged (45 days old) flies localizes especially to the brain areas 
receiving retinal input, the medulla and lamina (Myllykangas et al. 2005). Thus, the retinal 
pathology was further characterized in this study. The 45 days old cathD1 retina showed 
vacuolization (Fig. 2A in I), a finding indicative of cell death and typical for Drosophila models 
of neurodegenerative diseases (Kretzschmar 2009). Compared to many previously described 
neurodegenerative mutant Drosophila, the cathD1 retinal vacuolization was rather modest and 
late appearing. However, it was specific to the cathD1 mutation, since the phenotype was 
rescued by the expression of the cathD gene (Fig. 2B in I). This could be established through 
the use of the UAS-GAL4 system, where elav-GAL4 targeted the UAS-cathD expression to 
neurons and photoreceptor cells (Robinow & White 1988; Robinow & White 1991). 
Pathological changes in the retina are consistent with the results from previously described 
CTSD deficiencies. The Ctsd–/– mouse shows prominent retinal atrophy and apoptotic 
photoreceptor cell death (Koike et al. 2000; Koike et al. 2003). In human disease both 
congenital and juvenile onset CLN10 is characterized by evident retinal atrophy (Brown et al. 
1954; Steinfeld et al. 2006). A significant reduction in CTSD enzymatic activity may be 




with residual CTSD activity does not present with visual impairment (Awano et al. 2006; 
Evans et al. 2005). 
CTSD has been implicated as the major protease involved in photoreceptor turnover 
(Rakoczy et al. 1996; Regan et al. 1980). Retinal pigment epithelial cells are involved in the 
phagocytosis of photoreceptor debris by their microvilli that penetrate to photoreceptor cell 
layers (Strauss 2005). The presence of a mutated or inactive CTSD in retinal pigment 
epithelial cells correlates with the efficacy of photoreceptor clearance both in vitro and in vivo 
and affects the survival of these cells in aging mice (Rakoczy et al. 1996; Rakoczy et al. 1997; 
Rakoczy et al. 2002; Zhang et al. 2002; Zhang et al. 2005). Furthermore, the recently generated 
zebrafish model of CTSD deficiency was shown to lack the microvillar structures that are 
required for the phagocytosis (Follo et al. 2011). Since Drosophila and vertebrate retinal 
pigment cells share functional properties (Wang & Montell 2007), retinal degeneration 
observed in cathD1 Drosophila could be caused by dysfunctional retinal pigment cells. 
5.1.2 GENETIC MODIFIER STUDIES IN cathD1 DROSOPHILA (I) 
The retinal degenerative phenotype of cathD1 was utilized to screen for the effects of 
candidate modifiers, in order to to link cathD to genetic pathways relevant for NCL 
pathogenesis. Due to the relative mildness of cathD1 retinal pathology, only enhancement of 
the phenotype could be screened for. In addition, the requirement of histological analyses to 
observe modifications excluded the use of large-scale screening. However, 17 candidate 
mutant lines (Table 4) were studied representing biological processes previously described to 
be affected by CTSD deficiency and/or NCL disease (see Table 4 and Table 1 in I). An 
mRNA expression database FlyAtlas (www.flyatlas.org) was used to confirm the expression 
of these candidates in Drosophila eye. Based on the analysis of the Drosophila carrying cathD1 
together with the candidate modifier mutation, 7 candidate mutants were shown to enhance 
the cathD1 retinal pathology. Here, the results of the screen are discussed focussing on 
Drosophila pathways of lipid metabolism regulation (section 5.1.2.1) and on the common 
themes found in the modifier screens in different Drosophila models for NCL disease (section 
5.1.2.2). 
5.1.2.1 Genes involved in lipid metabolism 
The sphingolipid biosynthetic pathway is well-conserved and most genes in the pathway are 
shared between Drosophila and vertebrates (Acharya & Acharya 2005), Fig. 16. In this study, 
we focussed on the ceramide synthase schlank, a Drosophila homologue of the yeast longevity 
assurance gene, lag1. The homozygous lethal lag1G0061 Drosophila line carries a P-element in 
the 5’ coding sequence of the lag1 gene. lag1 was shown to act as a ceramide synthase that 




lag1G0061 enhanced the cathD1 degeneration, indicating that reduced ceramide synthesis has a 
detrimental effect on the cathD deficiency. 
 
Figure 16. Sphingolipid and mevalonate pathways in Drosophila. Pathways are simplified to illustrate 
the selected candidate genes (circled) and their functions. The sterol branch of the mevalonate 
pathway is lost in insects. lag1, longevity assurance gene homologue; CDase, Ceramidase; HMG-CoA, 
3-hydroxy-3-methyl-glutaryl coenzyme A; Hmgcr, HMG-CoA reductase; loe, AMP-activated protein 
kinase gamma subunit. 
 
Overexpression of the Drosophila neutral ceramidase, CDase, which converts ceramide to 
sphingosine, did not have an effect on the retinal phenotype of cathD1. Ceramide has been 
shown to bind and activate CTSD and affect its targeting, especially when excess ceramide is 
present (De Stefanis et al. 2002; Heinrich et al. 1999). However, since we did not test the effect 
of excess ceramide on the cathD1 pathology by overexpressing ceramide synthase lag1 or 
deleting the CDase activity, this aspect requires further studies in cathD1 Drosophila. 
Saposins are involved in glycosphingolipid catabolism and have previously been reported to 
affect CTSD maturation and transport (Gopalakrishnan et al. 2004; Laurent-Matha et al. 2002; 
Zhu & Conner 1994). In addition, CTSD has a role in prosaposin maturation (Hiraiwa et al. 
1997). Furthermore, saposins A and D are the major protein components of storage in 
human and ovine CLN10 disease (Siintola et al. 2006; Tyynela et al. 2000). Mutated Drosophila 
saposin-related, a homologue of prosaposin, did not enhance retinal degeneration of cathD1 
either in a heterozygous or homozygous state. 
Overexpression of Drosophila HMG-CoA reductase homologue, columbus (Hmgcr, clb), 
enhanced the cathD1 phenotype in our study. The highly conserved HMGCR functions in the 
mevalonate pathway responsible for sterol and isoprenoid biosynthesis, and it is the primary 
target of therapies to regulate cholesterol levels (Burg & Espenshade 2011). Indeed, abnormal 
cholesterol levels and trafficking characterize CTSD deficiency both in mouse and in human 




HMGCR by a study where atorvastatin, an HMGCR inhibitor, was shown to negatively 
regulate the level of CTSD expression in atherosclerotic plaques (Duran et al. 2007). 
The Drosophila mevalonate pathway does not, however, participate in de novo cholesterol 
synthesis although many genes and regulatory mechanisms are conserved (Gertler et al. 1988, 
Fig. 16). The mevalonate pathway controls the biosynthesis of isoprenoids, which have been 
shown to act as chemoattractants in migrating germ cells in Drosophila (Santos & Lehmann 
2004). Mevalonate is a precursor for the insect juvenile hormone, JH (Belles et al. 2005). 
While cathD1 does not appear to have a developmental phenotype, these pathways are not 
obvious mechanisms through which the Hmgcr would enhance the cathD1 adult-onset 
degenerative phenotype. It is of note that accumulation of isoprene compounds, dolichols, 
have been observed in many forms of NCLs (Rider et al. 1992). It is possible that the 
increased production of dolichols by Hmgcr overexpression contributes to the enhancement 
of retinal pathology in cathD1. 
The effect of AMP-activated protein kinase subunit  homologue löchrig (loe) was selected as a 
candidate because of its inhibitory action towards Hmgcr (Tschape et al. 2002, Fig. 16). Since 
the Hmgcr pathway appears to affect the cathD1 induced degeneration, introducing extra copies 
of loe could be beneficial to the degeneration of cathD1 mutant. Unfortunately, due to not 
being able to observe suppressive effects to the cathD1 phenotype, we were unable to assess 
this in our study. 
These results warrant further studies of the involvement of lipid metabolism regulation in 
CLN10. Specifically, ceramide synthesis and mevalonate pathway should be studied 
biochemically and in the Ctsd–/– mouse to clarify their role in CTSD functions and CLN10 
disease. While the effects of genetic modifications are more laborious to study in the mouse, a 
treatment with HMGCR inhibiting statins could be an achievable assay to perform. 
5.1.2.2 Common pathways with other NCL proteins? 
Drosophila models have been generated for two other NCL diseases, CLN1 and CLN3 (Table 
7). The Drosophila Ppt1 and Cln3 deficiencies present with NCL-like phenotypes (Hickey et al. 
2006; Tuxworth et al. 2011). In addition, overexpression models have been generated which 
lead to rough eye phenotypes (Korey & MacDonald 2003; Tuxworth et al. 2009; Tuxworth et 
al. 2011). The CLN3 overexpression model also shows Notch-like wing, bristle and 
macrochaetae phenotype (Tuxworth et al. 2009). These models have been used for unbiased, 
large-scale genetic modifier screening (Table 7). While these screens have been performed in 
overexpression models, it is of note that our cathD1 screen utilized the loss-of-function model 





There are no individual modifier genes that would be shared between the three NCL proteins 
(Table 7). However, especially cathD and Ppt1 may share genetic pathways of 
endocytosis/synaptic functions and lipid regulation (Buff et al. 2007). Both Cln3 deficiency 
and overexpression appear sensitive to oxidative stress (Tuxworth et al. 2011) which may be 
the case for cathD1 as well. These pathways are discussed in more detail below. 
The fact that cathepsin B, CG10992, was identified as a weak enhancer of cathD1 may indicate a 
role for cathepsin B in NCL pathogenesis. Interestingly, the Cathepsin B / Cathepsin L 
double knock-out mouse closely resembles the Ctsd–/– mouse and shows similar storage 
material accumulation (Koike et al. 2005). 
Synaptic functions/endocytosis 
CTSD is involved in the proteolysis of presynaptic -synuclein, accumulation of which causes 
Parkinson’s disease through a toxic effect (Cullen et al. 2009; Feany & Bender 2000). 
Aggregates of -synuclein were found in human, mouse and sheep CLN10 tissue, indicating 
that -synuclein toxicity might contribute to CLN10 disease (Cullen et al. 2009). These 
findings were confirmed in Drosophila, where enhanced retinal pathology was observed 
through the expression of human -synuclein (the Drosophila genome itself lacks -synuclein 
gene) in the cathD1 background (Cullen et al. 2009). 
In our study mutated Drosophila dynamin, shibire, enhanced cathD1 degeneration. Dynamin/shi 
functions in endocytosis and synaptic vesicle recycling (Robinson 2007; Seto et al. 2002; van 
de Goor et al. 1995), yet the enhancement effect may be caused by the disturbed endocytic 
properties of shi. The temperature sensitive mutant shi1 used in this study was not activated, 
and no synaptic phenotype has been suggested for shi1 under permissive temperatures 
(Kawasaki et al. 2000; van de Goor et al. 1995). The mouse Dynamin 1 mutant also needs to 
be challenged for the synaptic phenotype, yet endocytic failure was observed without 
stimulation (Ferguson et al. 2007). In addition, Drosophila shi1 has been shown to modify the 
phenotype of liquid facets, a Drosophila epsin involved in clathrin dependent endocytosis even in 
permissive temperatures (Cadavid et al. 2000), suggesting that the shi1 allele may cause an 
effect combined with other mutations in the shared pathway. Further supporting the 
importance of endocytic defects in cathD1 pathology, Target of rapamycin, Tor, and Hsc70-4 were 
identified as additional modifiers. A genetic interaction between Tor, Hsc70-4 and shi has been 
described in substrate specific endocytic degradation (Hennig et al. 2006), a process to which 
cathD could logically connect. 
The Drosophila cathD1 synaptic phenotype was examined in the 3rd instar larval neuromuscular 
junction, but the cathD1 mutation did not appear to have an obvious effect on the size and 
distribution of synaptic boutons (unpublished observations, M. Kuronen, R.I. Tuxworth, G. 




properties in cathD1, since presymptomatic accumulation of readily releasable synaptic vesicles 
and decreased frequency of miniature excitatory postsynaptic currents have been observed in 
Ctsd–/– mice (Koch et al. 2011; Partanen et al. 2008). 
In the Ppt1–/– mouse model of CLN1 disease, abnormal synaptic properties have been 
observed in the cortical neuron cultures (Virmani et al. 2005). Synaptic changes have also been 
postulated to precede the pathology of these mice (Kielar et al. 2009; Kim et al. 2008). Indeed, 
a clear effect of the synaptic/endocytosis related genes to the Drosophila Ppt1 overexpression 
phenotype has been observed (Buff et al. 2007, Table 7). Interestingly, DNAJC5/CSP, a 
recent addition to the list of NCL causative genes, could be modelled with Drosophila cysteine 
string protein mutants that cause impaired presynaptic neurotransmission and 
neurodegeneration (Noskova et al. 2011; Umbach et al. 1994; Zinsmaier et al. 1994). Thus, 
synaptic pathology is one of the common themes not only between different NCL subtypes 
but also between different animal models of NCLs. 
Oxidative stress 
Another such theme may be the sensitivity to oxidative stress, which has been proposed as a 
mechanism of neurodegeneration in NCL pathogenesis (Wei et al. 2008). Antioxidant dietary 
supplementation has been of slight benefit in human CLN3 patients (Santavuori et al. 1989) 
and the antioxidant therapy with resveratrol has shown beneficial effects in the Ppt1–/– mouse 
(Wei et al. 2011) and in Cln3 deficient mouse cells (Yoon et al. 2011). CTSD has also been 
linked to oxidative stress induced apoptosis (reviewed in Pivtoraiko et al. 2009). The Drosophila 
cathD may also participate to oxidative stress-related pathways, since we found that the 
mutated thioredoxin-reductase, Trxr-1, enhanced the cathD1 degenerative phenotype. Trxr-1 and 
the Superoxide dismutase (Sod) / catalase constitute the most important defense systems against 
oxidative damage in Drosophila (Missirlis et al. 2001). Yet the cathD1 phenotype was unaffected 
by the Sod mutation, indicating that the Trxr-1 pathway is of specific importance in cathD1 
induced pathology. Oxidative stress related pathways appear also affected in the CLN3 
Drosophila models. Sod and catalase overexpression rescued the eye phenotype of Cln3 
overexpressing Drosophila (Tuxworth et al. 2011). The lifespan of Cln3 deficient Drosophila was 
decreased under induced oxidative stress (Tuxworth et al. 2011), however, H2O2 induced 
oxidative stress showed no significant effect on the cathD1 lifespan (unpublished observations, 
M. Kuronen, M. Talvitie, L. Myllykangas). 
Comparison between the different NCL Drosophila models is now possible. The modifier 
effects observed in one model could be tested in other models to achieve conclusions on the 
involvement of a genetic pathway for different Drosophila NCL genes. As such, assessment of 
highly conserved synaptic functions and oxidative stress pathways in Drosophila would benefit 





Table 7. Drosophila models of NCL disease. 
Model, phenotype Modulators, pathways 
cathD1 
Modest neurodegeneration, typical NCL 
storage material accumulation (1) 
Endocytosis: Shi (I) 
Chaperone: Hsc70-4 (I) 
Lipid metabolism-related: lag1, Hmgcr (I) 
Lysosomal: CG10992 (Cathepsin B) (I) 
Oxidative stress: Trxr-1 (I) 
Synaptic: α-synuclein (2) 
Ppt1 deficiency 
Modest reduction in lifespan, storage 
material accumulation (3), defective 
endocytic trafficking (4) 
_ 
Ppt1 overexpression 
Rough eye (5) 
Synaptic: endophilin A, blue cheese, synaptotagmin, stoned A, IGF-II mRNA 
binding protein (6, 4) 
Lipid metabolism: phosphatidylserine decarboxylase, ATP-binding cassette 
homolog (6) 
Chaperone: Hsc70-3 (6) 
Zinc transport: Fear of Intimacy (4) 
Phosphorylation: C-terminal Src kinase (4) 
Sumoylation: Smt3 (4) 
Bone morphogenetic protein signaling: Twisted gastrulation (4) 
Cln3ΔMB1 
Modest reduction in lifespan, no storage, 
hypersensitivity to oxidative stress (7) 
_ 
Cln3 overexpression 
Rough eye, Notch-like phenotype (7, 8) 
JNK pathway: basket, hemipterous, puckered (8) 
Stress responses and apoptosis: MAP kinase kinase kinase 1, thioredoxin 
peroxidase (JafRac2), Tollo, falafel, thread (7) 
RNA processing and translation regulation: boule, pumilio, alternative 
splicing factor (Rox8) (7), mago nashi, tsunagi (8) 
Notch signaling: Hairless, E(spl) region transcripts m5 and m7 (7) 
Neurodegenerative disease-associated genes: Molybdenum cofactor 
biosynthesis protein 1 (7) 
Protein turnover and stability: cullin-5, septin interacting protein 3, vihar (7) 
Vesicle trafficking:schizo, like-AP180, signal recognition particle 9kD (7) 
Cytoskeletal regulation and small GTPase signaling: tarsal-less, 
microtubule associated protein 205, Small Protein Effector of Cdc42, klarsicht 
(7) 
Ras signaling: MAP kinase phosphatase 3, daughter of sevenless, pointed (7) 
Transcriptional regulation and chromatin remodeling: without children, 
stonewall, jim, jing interacting gene regulatory 1, serendipity β, methyl-CpG-




Table 7 continued. Phenotypes for different models are summarized, together with the results from 
genetic modifier studies. References: I, Study I of this thesis, 1) Myllykangas et al. 2005, 2) Cullen et al. 
2009, 3) Hickey et al. 2006, 4) Saja et al. 2010, 5) Korey & MacDonald, 2003, 6) Buff et al. 2007, 7) 






5.2 NEUROPATHOLOGY OF THE Cln8mnd MOUSE 
The Cln8mnd mouse is characterized with retinal degeneration, behavioural abnormalities and 
motor deficits that lead to premature death (Bolivar et al. 2002; Chang et al. 1994; Messer & 
Flaherty 1986; Messer et al. 1987; Messer et al. 1993). In this part of the work, the brains of 
presymptomatic/early symptomatic (1-3 months of age), moderately symptomatic (5 months) 
and late symptomatic (8 months) Cln8mnd mice were analysed. Observed neuron loss and glial 
activation is discussed in sections 5.2.1 and 5.2.2. A specific defect in galactolipid content and 
synthesis was accompanied by a myelination delay that preceded any observed pathological 
changes in the brains of the Cln8mnd mouse (sections 5.2.3 and 5.2.4). Finally, the sequence of 
these changes and their possible significance for CLN8 disease are discussed in sections 5.2.5 
and 5.2.6. 
5.2.1 NEURON LOSS IN SENSORY AND MOTOR PATHWAYS (II, UNPUBL.) 
We studied neuron loss in Cln8mnd mouse brains by assessing stereological cell counting 
methods. Disease progression was analysed in sensory thalamocortical pathways, which have 
previously been shown to be affected in NCL disease (reviewed in Cooper 2010). Due to the 
motor neuron degeneration phenotype of the Cln8mnd mouse (Messer et al. 1986; 1987) the 
pathology of the motor cortex was also investigated. 
5.2.1.1 Somatosensory thalamocortical pathway is affected first in Cln8mnd 
Within the sensory pathways studied, neuron loss showed earliest onset in the Cln8mnd 
somatosensory thalamocortical pathway (Fig 5 in II). The thalamic ventral posterior complex, 
VPM/VPL, had lost 20% of neurons at 5 months of age. Similar redution was seen in the 
somatosensory cortical layers IV and VI that receive thalamic inputs or project to the 
thalamus. The somatosensory pathway is also affected in other mouse models of NCLs 
(Kielar et al. 2007; Partanen et al. 2008; Pontikis et al. 2005; von Schantz et al. 2009). Abnormal 
somatosensory evoked potentials (SEPs) in NCL patients further underline the relevance of 
somatosensory defects in NCL disease (see section 5.2.6). 
5.2.1.2 Visual thalamocortical pathway is affected late in comparison to the Cln8mnd 
retinal pathology 
Visual loss is a prominent symptom in most forms of human and animal NCL disease 
(Jalanko & Braulke 2009). Retinal degeneration, with varying onset and severity, is observed 
in most NCL mouse models. Cln8mnd photoreceptor loss is evident from postnatal day (P) 15-




2 months onward and becomes undetectable by 6 months (Chang et al. 1994). Thus, it is 
intriguing that in our thalamocortical analysis we found evidence of largely intact visual cortex 
and thalamus until the late symptomatic, 8 month old Cln8mnd mouse (Fig. 9 in II), when 60% 
of the neurons in LGNd and 20% in visual cortex were lost. This suggests that the visual 
areas of the Cln8mnd brain remain intact for a markedly long period of time after dimimished 
or lost input signal from the retina. 
This sequence of events in the visual pathway distinguishes Cln8mnd from previously 
characterized NCL mouse models (Fig. 17), although absolute comparisons cannot be made 
e.g. due to the effects of different strain backgrounds. A completely reversed sequence 
appears in Cln3–/– mice where the retina remains functionally intact, as assessed by ERG at 
12 months, and shows mild apoptosis only at 18 months (Seigel et al. 2002). The optic tract 
conduction velocity is reduced already at 6 months of age with a concomitant neuron loss in 
LGNd (Weimer et al. 2006). The visual cortex was not assessed in these mice, which carry an 
exon 1-6 deletion, yet in Cln3Δex7/8, with a deletion of Cln3 exons 7 and 8, cortical thinning 
and neuron loss were observed at 12 months of age (Pontikis et al. 2005). 
Yet another sequence is found in Ppt1 and Cln5 deficiency, where the retina and either one of 
the visual thalamocortical pathway components are affected concomitantly (Fig. 17). The 
Ppt1–/– mice show reduced ERG response from 2 months onwards and significant loss of 
photoreceptors at 5 months (Griffey et al. 2005). Loss of LGNd neurons is evident from 3 
months onwards, whereas cortical neuron loss begins at 5 months (Kielar et al. 2007). In 
Cln5–/– mice visual cortical neurons are lost from 4 months onwards, but in thalamic LGNd 
neuron loss was observed only at 12 months (von Schantz et al. 2009). In these mice loss of 
vision occurs at 4-5 months of age, assessed by the forelimb extension test (Kopra et al. 2004). 
Of other NCL mouse models, Ctsd–/– shows retinal thinning at P12 and photoreceptors are 
nearly abolished by P25, while the mice die at P262 (Koike et al. 2003). Visual cortical 
thinning was observed at the end stage of the disease (Partanen et al. 2008), however, the 
visual pathway has not been systematically studied in these mice. The Cln6nclf mouse is 
phenotypically very similar to Cln8mnd, although demonstrating slightly delayed pathology 
(Bronson et al. 1998). Retinal cell loss is demonstrated by 4 months of age (Bronson et al. 
1998), but to date thalamocortical pathology of Cln6nclf has not been described. 
Apart from the photoreceptor cell loss, which is observed early, the Cln8mnd retinal ganglion 
cells appear to contain storage material as early as from P0 (Seigel et al. 2005; Chang et al. 
1994) and may thus have compromised functions. It is not clear why the retina shows specific 
sensitivity in Cln8mnd disease. Cln8mnd retinal pathology has been linked to oxidative stress 
(Guarneri et al. 2004). CLN8 has been linked to many other mechanisms, which may have 
particular effect in the retina, such as mitochondrial dysfunction or calcium signalling 






Figure 17. Comparison of the onset of retinal and visual thalamocortical pathology in the mouse 
models of NCL disease. The X axis represents mouse age in months and the reported lifespan of the 
models is indicated with boxes (Cln3 and Cln5 deficient mice survive beyond 18 months of age). 
Ctsd-/- and Cln6nclf mice are not illustrated since the thalamocortical pathology is not well described. 
thal, thalamus (LGNd); ctx, cortex (V1). 
 
5.2.1.3 Neuron loss progresses more rapidly in the Cln8mnd thalamus 
The sequence of thalamocortical pathology appears to vary within the NCL mouse models, 
which is also illustrated by Fig. 17. The thalamus appears to be the primary site of pathology 
in Ppt1 and Cln3 deficiencies, (Griffey et al. 2005; Kielar et al. 2007; Pontikis et al. 2005; 
Weimer et al. 2006) while cortical cell loss appeared first in the Cln5–/– mouse (von Schantz et 
al. 2009). In the Cln8mnd mouse the thalamic and cortical areas were affected concomitantly, 
however, neuron loss was more pronounced and progressed more rapidly in the thalamic 
VPM/VPL and LGNd (Fig. 5 and 9 in II). 
Thus it appears that thalamic neurons are more susceptible to NCL-related neuron loss than 
their cortical counterparts. This may arise from multiple causes. Thalamic neurons may be 
more sensitive to storage material accumulation, however, all NCL mouse models contain 
subcellular storage, yet the timing of thalamic pathology is different. The primary defect could 
be dysfunctional signalling from other regions of the CNS. This hypothesis would be 
favoured by a CLN3 study, where decreased optic nerve conductivity and LGNd pathology 
were concomitantly observed (Weimer et al. 2006). Since the thalamus is a major relay system 
in corticocortical pathways, thalamic neuron loss may arise from the dysfunction in cortical 
signalling. These aspects, such as determining the rate of storage material accumulation in 




5.2.1.4 Primary motor cortex shows late onset neuron loss in Cln8mnd 
Since Cln8mnd mice present with the pathology of upper (motor cortical) and lower (spinal 
cord) motor neurons and progressive motor deficits, it was originally characterized as an ALS 
model (Messer and Flahety 1986; 1987), see Fig 14. Here, we studied the effect of the Cln8mnd 
mutation in the primary motor cortex (M1). As with the visual cortex, Cln8mnd motor cortex 
appears to retain its integrity until the end-stages of the disease, since neuron loss was 
observed only in 8 month old animals (Fig. 18; unpublished). At this age, approximately 20% 
of neurons in layers V and VI were lost. Layer V contains the large pyramidal neurons that 
send their axons to synapse with lower motor neurons in the spinal cord (Kandel et al. 2000). 
This neuron loss indicates diminished potential for motor commands from the cortex when 
motor symptoms are already evident. 
 
Figure 18. Late-onset neuron loss in the primary motor cortex (M1) of Cln8mnd mouse and no 
presymptomatic abnormalities in the peripheral nerve conduction. A) Schematic representation of M1 
in a bisected coronal section of a mouse brain. B, C) As quantified using the stereological optical 
fractionator, neuron numbers are reduced in layers V and VI by 20% in 8 month old Cln8mnd. D) 
Schematic illustration of the mouse sciatic nerve. E) There was no reduction in Cln8mnd nerve 
conduction velocity, measured from the motor evoked potentials of sciatic nerve in 1 and 4 month old 
mice. Data represented as mean + standard error (B,C) and standard deviation (E). mo, month(s) old. 
 
The Cln8mnd spinal cord pathology has been investigated in a number of studies, showing 
neurodegeneration, accumulation of storage material and glial activation (Callahan et al. 1991; 




systematically collected data exist on the quantity of neuron loss. Yet it appears to be quite 
mild (over 80% of neurons are spared at 7 months of age, Gorio et al. 1999) or not different 
from wildtype (a study in 8-9 month old Cln8mnd mice by Zeman et al. 2004). Thus, it appears 
that the onset of motor symptoms is triggered by a dysfunction in upper and/or lower motor 
neurons rather than their overt loss. We preliminarily assessed this question by studying the 
Cln8mnd mouse peripheral nerve function. We measured the motor evoked potentials prior to 
the onset of motor symptoms in 1 and 4 month old Cln8mnd mouse sciatic nerve (Fig. 18; 
unpublished). The Cln8mnd nerve conduction velocities were not different from wildtype, 
indicating that peripheral axonal conduction is not compromised in these early symptomatic 
mice. Unfortunately, our analysis did not include later stages of the disease or, despite 
repeated attempts, quantify the motor cortical potentials. 
While our study does not form a complete picture of the motor pathway, we did 
comprehensively assess cortical integrity and peripheral nerve functionality. Our results 
combined with previous descriptions of the spinal cord pathology suggest that in the 
corticospinal motor pathway, the peripheral component degenerates concomitantly with the 
motor cortex and that these changes largely coincide with the observed motor symptom 
onset. The cerebellum, brain stem, thalamus and basal ganglia are also involved in motor 
functions and their regulation and furthermore, the motor systems receive feedback from the 
sensory pathways (Kandel et al. 2000). These aspects require further studies in the Cln8mnd 
mouse. 
5.2.2 GLIAL ACTIVATION (II, UNPUBL.) 
Glial activation has been shown to precede neuron loss in previously analysed NCL models 
(Cooper 2010). Similarily, astrocytosis but especially microglial activation occurred early in the 
Cln8mnd mouse. CD68 positive microglia with reactive appearing morphology were present at 
3 months of age in Cln8mnd somatosensory, visual and motor pathways. Microglial activation 
occurred well before neuron loss, especially in visual and motor pathways where neuron loss 
was observed only at 8 months (Fig. 19 and Figs 7, 8 in II). Similar findings have been 
reported in Cln8mnd hippocampus and spinal cord where GFAP positive astrocytes and cluster 
of differentiation 11b (CD11b) positive microglia are present at 4-5 months of age (Mennini 
et al. 2004, Melo et al. 2010). 
5.2.2.1 Role of glial activation in disease? 
Dual roles for microglia have been proposed in neurodegenerative diseases such as 
Alzheimer’s disease. Microglial activation appears to be neuroprotective through inducing 
amyloid β phagocytosis and proteolysis, while detrimental effects are mediated by the 




suggested to phagocytose NCL storage material, implicated by the microglial localization of 
mitochodrial ATP synthase subunit c in Ctsd–/– mouse brain. However, it appears that Ctsd–/– 
microglia, not only neurons, accumulate storage material since in vitro microglia without 
neurons also contain subunit c (Nakanishi & Wu 2009). The presence of storage material 
might compromise normal functions and signalling of microglia and lead to neurotoxicity, for 
instance through nitric oxide overproduction which is observed in Ctsd–/– mice (Nakanishi et 
al. 2001; Yamasaki et al. 2007). 
In addition, there is evidence of increased pro-inflammatory signaling in the Cln8mnd mouse. 
Levels of tumor necrosis factor alpha, TNFα, and its receptor have been shown to be 
elevated in Cln8mnd mouse brain and spinal cord (Galizzi et al. 2011; Ghezzi et al. 1998; Melo et 
al. 2010; Mennini et al. 2004). Due to the pro-inflammatory nature of TNFα, its upregulation 
is likely to be detrimental to Cln8mnd neurons. 
 
 
Figure 19. Glial activation precedes neuron loss also in the primary motor cortex of Cln8mnd mice. A) 
GFAP staining shows activation of astrocytes, especially in layers V and VI, already at 5 months of 
age. B) Microglial activation is evident in CD68 staining especially in layer V. Scale bars 200 µm. 
 
The major astrocytic glutamate transporter GLT-1 has been shown downregulated in Cln8mnd 




GFAP expression indicates a specific reduction in the properties of glutamate recycling in 
Cln8mnd reactive astrocytes (Mennini et al. 1998). Reduced expression of GLT-1 has been 
observed in various neurodegenerative diseases such as ALS and Alzheimer’s disease 
(Maragakis & Rothstein 2006; Sofroniew & Vinters 2010). A defective glutamate cycle may 
cause excitotoxicity and contribute to the seizure phenotype of the Cln8mnd mouse (Melo et al. 
2010). 
The function of reactive astrocytosis in NCL disease was recently investigated in a CLN1 
mouse model without the ability to upregulate astrocytic intermediate filaments, a hallmark of 
reactive astrocytosis. The Ppt1–/–, Gfap–/–, Vimentin–/– triple knockout mouse shows earlier 
disease onset and increased neurodegeneration, possibly due to increased neuroinflammation 
mediated by microglial activation, an overt increase in pro-inflammatory cytokines and 
immune cell infiltration to the CNS (Macauley et al. 2011). This implies that reactive 
astrocytes, by diminishing the inflammatory reaction in the brain, may have protective effects 
in NCLs. 
5.2.2.2 Differential glial activation in Cln8mnd thalamic pathways  
While in the late stages of Cln8mnd disease glial activation is widespread, it does not affect all 
areas of the brain identically (Table 8). Apart from primary sensory and motor 
thalamocortical pathways, the posterior thalamic nucleus – somatosensory cortex pathway 
showed obvious glial activation in Cln8mnd. This pathway was not investigated for neuron loss 
in this study, and has not been analysed in other NCL models. Interestingly, in the mouse 
model of another neurodegenerative epilepsy syndrome, progressive myoclonus epilepsy 
EPM1, this pathway showed neuron loss and glial activation (Tegelberg et al. 2012).  
The reticular thalamic nucleus, which performs the major inhibitory action in the rodent 
thalamus, showed activation of both microglia and astrocytes in Cln8mnd. The Ppt1–/– reticular 
nucleus is affected by neuron loss and glial activation (Kielar et al. 2007). Loss of the 
inhibitory influence of the reticular nucleus may contribute to the death of thalamic relay 
neurons or affect the seizure phenotype of Cln8mnd mice (Melo et al. 2010). 
The olfactory sensations from olfactory cortex (piriform cortex) are relayed by the thalamic 
medial dorsal nucleus, which appears affected in the Cln8mnd mouse. Degenerative changes 
were observed in the olfactory pathway of the CLN2 mouse model, Tpp1–/– (Sleat et al. 2004). 
The limbic system pathology may be significant in the Cln8mnd mouse, since clear glial 







Table 8. Microglial activation and astrocytosis in the 8 month old Cln8mnd mouse thalamocortical 
pathways.  
  
Degree of glial activation was determined from GFAP and CD68 stained brain sections by observing 
the region full of intense staining (three symbols);less than half of the region stained (two symbols);or 
few scattered cells (one symbol) in Cln8mnd compared to wt). Yellow symbols represent microglial 
activation (CD68) and red astrocytosis (GFAP). n=6 per genotype and age. 
 
5.2.3 MYELINATION (III, UNPUBL.) 
Even prior to microglial activation, we observed a developmental delay in the myelination of 
Cln8mnd mouse brains. In addition, a specific function for CLN8 in myelin formation was 
indicated by the expression pattern of Cln8. In the developing brain the expression of Cln8 
mRNA was induced at the beginning of myelinogenesis and downregulated after 1 month of 
age (Fig 5A in III). Of the in vitro CNS cell types studied, Cln8 was expressed most by the 
oligodendrocytes (Fig 5B in III). Similar results have been observed in previous studies, 
where the expression of Cln8 was found to peak in early postnatal development (Lonka et al. 




oligodendrocyte differentiation by comparative microarray analyses of different CNS cell 
types (Cahoy et al. 2008; Fulton et al. 2011). Of other NCL genes, expression of Cln5 appears 
also to be induced during oligodendrocyte maturation (Cahoy et al. 2008; Fulton et al. 2011). 
and decreased myelination and oligodendrocyte maturation was shown to characterize the 
early disease of Cln5–/– mice (Schmiedt et al. 2012). 
As a whole, myelination has not received detailed attention in NCL research, since it does not 
appear primarily affected in NCL disease. Myelination requires the repid and well-
orchestrated synthesis and transport of the myelin membrane components (see section 
2.1.3.1). Since the cellular transport pathways are probably affected in most NCLs, it is not 
surprising that there would be effects to the myelination process as well. In addition, 
myelinating cells could therefore be useful tools to study NCL-related trafficking defects. 
5.2.3.1 Delayed myelin maturation in early Cln8mnd disease 
A moderate decrease in brain myelin was found to characterize especially the early 
symptomatic Cln8mnd mice. The thinning of Cln8mnd mouse white matter tracts, including the 
corpus callosum, anterior commissure and internal capsule, was evident in 1 and 3 month old 
mice (Fig. 3 in III). Likewise, reduced immunostaining of myelin markers MBP, PLP and 
MOG was observed in 1 month old Cln8mnd brain samples (Fig. 2 and 5 in III). The mRNA 
expression of Mbp and Mog was also reduced (Fig. 5 in III). Ultrastructural analysis of myelin 
showed thinner myelin sheets in Cln8mnd brains (Fig. 4 in III) suggesting that the myelination 
defect is due to the inability of Cln8mnd to produce sufficient amounts of myelin membrane. 
Indeed, Cln8mnd oligodendrocytes showed reduced expression of mature, myelinating 
oligodendroglial markers Mbp and Mog in vitro, while the expression of early markers Ng2 and 
Olig2 were normal (Fig. 7 in III). Thus, we propose that the observed decrease in myelination 
is due to delayed oligodendrocyte maturation and myelin membrane production in the 
Cln8mnd mouse. Functionally, the Cln8mnd myelin itself appears normal, since we were unable 
to show dramatic disturbances in white matter integrity, as measured by diffusion tensor 
imaging in 4 month old Cln8mnd mice. Nerve conduction velocity was also normal in Cln8mnd 
peripheral nerves (Fig. 18), indicating preserved insulation capacity of Cln8mnd myelin. 
5.2.3.2 Increased myelination in late stages of the disease? 
Reduction in myelin content was not observed later in disease and there was no evidence of 
late-onset demyelination in Cln8mnd mouse. White matter tract volumes or the expression of 
myelin markers were not different from wildtype in Cln8mnd mice of 4-5 months of age (Figs 
2, 3 and 5 in III). At 8 months of age, the corpus callosum thickness of Cln8mnd was similar to 





Figure 20. Increased MBP expression in the 8 month old Cln8mnd mouse. A) Corpus callosum 
thickness did not differ from wildtype at 8 months of age B) Frontal brain section of an 8 month old 
wildtype mouse. C) Frontal brain section of an 8 month old Cln8mnd mouse, showing increased MBP 
staining in corpus callosum, frontal cortex (motor and somatosensory areas) and in striatum. 
 
Surprisingly, in the end stage of Cln8mnd disease, we observed an increase in MBP staining in 8 
month old Cln8mnd mouse brains (Fig. 20 B, C). Since signals from reactive astrocytes promote 
myelination (Nash et al. 2011), increased MBP staining could reflect the presence of reactive 
glial cells in the Cln8mnd brains at this stage. 
5.2.4 ALTERATIONS IN LIPID METABOLISM (III, UNPUBL.) 
A role for CLN8 in lipid metabolism regulation has been proposed through its TLC protein 
domain possession (Winter and Ponting, 2002) and through the observed abnormalities in 
brain lipid composition in EPMR patients (Hermansson et al. 2005). In addition, hints 
towards a lipid regulatory role for CLN8 have come from another lysosomal storage disease, 
as CLN8 overexpression was recently shown to protect from severe phenotypes of Gaucher 
disease caused by glucocerebrosidase deficiency (Zhang et al. 2012). 
 
Fig 21. Free cholesterol content in the cerebral cortical tissue of mouse was similar to wildtype (wt). 
Ratio is given as cholesterol (nmol) to total phospholipids (nmol), error bars indicate standard 




A large-scale lipid profiling was performed to study the molecular events in the pathogenesis 
of Cln8mnd. By liquid chromatography / mass spectrometry, a reduction in galactolipids GalC 
and sGalC was observed (Fig 1 in III). The reduction was significant only in the early period 
of the Cln8mnd pathology (at one month of age). Later in disease, at 5 months, the level of 
sphingomyelin was slightly increased. The content of free cholesterol was normal (Fig 21). 
Since the galactolipids are myelin-specific, we analyzed the Cln8mnd brains for their 
myelination status. These findings were discussed in the previous section 5.2.3. 
In addition to the reduced galactolipid content, the key enzyme in galactolipid synthesis, 
CGT, showed moderately reduced activity in 1 and 5 month old Cln8mnd mice (Fig 1 in III). 
This persistent decrease may link CLN8 to the CGT enzyme and galactolipid synthesis. Both 
CLN8 and CGT are expressed by oligodendrocytes and subcellularly reside in the 
endoplasmic reticulum (Lonka et al. 2000; Lonka et al. 2004; Neskovic et al. 1986; Nilsson & 
Warren 1994; Schulte & Stoffel 1993; van Meer 1998). CLN8 has also been suggested to bind 
GalC and ceramide (Rusyn et al. 2008). Taken together, CLN8 could act as a mediator of 
galactolipid synthesis, but further studies will be needed to pinpoint the exact mechanism. 
Galactolipid synthesis deficient Cgt–/–mice are viable but show tremor, hindlimb paralysis and 
death in the end of the myelination period (Bosio et al. 1996; Coetzee et al. 1996). Surprisingly, 
Cgt–/– mutant mice display compacted myelin, yet the organization of myelin in the paranodal 
regions is abnormal, resulting in severe defects in myelin insulation properties (Bosio et al. 
1996; Coetzee et al. 1996; Marcus & Popko 2002). Based on these findings galactolipids have 
been postulated to be essential for proper axon-glial interactions in the paranodes (Marcus & 
Popko 2002). The axon-oligodendrocyte signaling may also be disrupted Cln8mnd mice, which 
show abnormal oligodendrocyte maturation and myelination defects.  
5.2.5 SEQUENCE OF EVENTS 
Taken together, we found notable effects of the Cln8mnd mutation on the mouse phenotype. 
The temporal relationship of abnormal myelin maturation, reactive changes in microglia and 
astrocytes together with neuron loss in the Cln8mnd mouse is presented in Fig. 22, which also 
summarises earlier knowledge on the Cln8mnd mouse pathology. 
Early studies on Cln8mnd mice characterized the disease progression based on the motor 
symptoms, and considered mouse age points until 5-6 months to be asymptomatic (Callahan 
et al. 1991, Messer and Plummer, 1993, Plummer et al. 1995). It is clear, however, that disease 
progression in the Cln8mnd mouse starts already earlier. This is evident especially in the Cln8mnd 
retina but also indicated by the early changes in Cln8mnd glial cells. 
Indeed, while the precise timing of thalamocortical pathology varies in different pathways, 




pathways studied in Cln8mnd mouse. Delayed myelination, which precedes these changes, was 
found in all Cln8mnd white matter tracts studied and is not restricted to the thalamocortical 
pathways. Abnormal myelination may affect the stability of axonal integrity and the neural 
circuits they form (Barres 2008; Nave 2010) while galactolipid deficiency results in inproper 
axon-oligodendrocyte signalling (Marcus & Popko 2002). These effects may be pronounced 
on long axons that could contribute to the pathology of cortical pyramidal neurons and 
thalamic relay neurons in the Cln8mnd mouse. 
 
Figure 22. Neuropathology of the Cln8mnd mouse. Mouse age is represented in months. 
Retinal/spinal cord pathology is represented by a light grey background and (thalamo)cortical changes 
by a dark grey background. 
 
Microglia and astrocytes may respond to abnormalities in the signalling between neurons and 
glial cells, or to the accumulating neuronal storage material. Loss of inhibitory interneurons 
(Cooper et al. 1999) and defects in astrocytic glutamate recycling (Mennini 1998) may induce 
excitotoxicity in Cln8mnd brain. This may be sensed by glial cells, which activate compensatory 
mechanisms such as microglia-mediated phagocytosis of excitatory synapses (Tambuyzer et al. 
2009). However, the effects of glial activation may be detrimental in Cln8mnd brain, as 
suggested by increased pro-inflammatory signaling (Galizzi et al. 2011, Ghezzi et al. 1998, 
Mennini et al. 2004, Melo et al. 2010). 
While thalamocortical pathology is evident in Cln8mnd brain, the origin of defects is not clear 
and may not be uniform across distinct pathways. The integrity of the somatosensory 




neurodegeneration in the spinal cord (Gorio et al. 1999; Zeman et al. 2004). Nevertheless, the 
pathology of sensory receptors connecting to spinal cord has not been studied. In the 
corticospinal motor pathway motor cortex and spinal cord show largely simultaneous 
pathology, although systematic analysis of these events is lacking and a thorough investigation 
of other regions involved in motor regulation would also be required. Finally, since these 
pathways are interconnected, the primary problems in the somatosensory pathway might be 
reflected as motor deficits in the Cln8mnd mouse. 
The sequence appears clearer in the Cln8mnd mouse visual pathway, where an abnormal input 
from the retina is likely to induce the thalamocortical pathology. There is a considerable delay, 
however, that would make the Cln8mnd mouse an appealing model system for future therapies 
in trying to correct the NCL-related, retinal-onset visual loss. . One such approach could be a 
gene transfer based therapy with neurotrophic factors, supported by the beneficial effect of 
insulin-like growth factor 1 treatment to the Cln8mnd neuropathology (Cooper et al. 1999). 
However, in order to prevent cell loss in retina, it needs to be targeted very early. 
5.2.6 SIGNIFICANCE TO HUMAN NCL DISEASE? 
There are two distinct human NCL diseases caused by mutations in CLN8. Our findings 
indicate that the Cln8mnd mouse is a better model for the late infantile onset NCL than for the 
protracted EPMR disease. Patients with late infantile CLN8 disease show abnormal or 
extinguished ERG and diminished or loss of visual evoked potential (VEP) responses (Allen 
et al. 2011; Cannelli et al. 2006; Ranta et al. 2004; Reinhardt et al. 2010; Topcu et al. 2004; 
Vantaggiato et al. 2009). EPMR disease is not characterized with retinal degeneration and only 
a subset of patients has diminished visual acuity and abnormal VEPs (Hirvasniemi et al. 1995; 
Lang et al. 1997). Somatosensory pathology is indicated by the presence of myoclonus in late 
infantile CLN8 patients (Allen et al. 2011; Cannelli et al. 2006; Kousi et al. 2009; Kousi et al. 
2012; Ranta et al. 2004; Reinhardt et al. 2010; Topcu et al. 2004; Vantaggiato et al. 2009; Zelnik 
et al. 2007). Myoclonus is not observed in EPMR and no alterations in somatosensory evoked 
magnetic fields were observed (Lauronen et al. 2001).  
The Cln8mnd mouse mutation predicts a truncated CLN8 protein or degradation of the Cln8 
mRNA (Ranta et al. 1999). However, according to the current knowledge on genotype-
phenotype correlations in CLN8 disease, the nature of the causative mutation does not 
explicitly underlie the differences between the two human CLN8 diseases. Most CLN8 
disease mutations are missense mutations (Kousi et al. 2012). The EPMR mutation is a 
missense mutation outside of the TLC protein domain (Ranta et al. 1999). Mutations that are 
not within the TLC domain can also cause the more severe late infantile CLN8 disease, thus 




Studying the Cln8mnd mouse has provided information on disease progression in yet another 
NCL model. The recognition of early glial activation and the role for the thalamus in the 
NCL disease progression have evolved from studies in animal models (Cooper 2010). While 
human studies are limited to fairly low-resolution imaging methods and to the use of post 





If you can look into the seeds of time, 
And say which grain will grow and which will not, 
Speak then to me. 
-William Shakespeare 
 
This thesis delineated cellular and molecular changes influencing the pathogenesis of neuronal 
ceroid lipofuscinosis (NCL) in two animal models, the cathepsin D deficient Drosophila model 
for CLN10 disease, cathD1, and the Cln8mnd mouse model for CLN8 disease. Since other NCL 
diseases have been previously modeled in mouse and Drosophila, we were able to compare our 
results to previous research. In addition, by utilizing these two systems, it was possible to 
compare the benefits and limitations of two different animal models. 
In Drosophila, effects of second-site mutations on the cathD1 degenerative phenotype were 
tested in vivo, an approach that would have been limited to only a few candidates in 
mammalian model systems. While the cathD1 Drosophila phenotype is recessive and relatively 
mild, a large-scale unbiased genetic modifier screen was infeasible, and thus the best potential 
of Drosophila modelling could not be exploited. However, by our hypothesis-based screen we 
were able to test different mechanisms that have been suggested relevant to CTSD induced 
neurodegeneration. Pathways related to endocytosis, oxidative stress and lipid regulation were 
proven applicable for future studies in Drosophila. 
The most widely used model system for NCL disease is the mouse. With the comprehensive 
characterization of the Cln8mnd mouse in this study, there is now a plethora of data from 
existing NCL mouse models. Some phenomena of NCL disease pathogenesis have 
specifically appeared through studying these mice, such as the relevance of neuron loss and 
glial activation in the thalamus. In human NCL patient brain imaging the thalamus shows 
pathological changes, which may prove to be important for the progression of the disease. 
Yet the cerebral cortical pathology is very pronounced in human NCLs while in mouse 
models such as Cln8mnd the cortex is relatively spared. Differences in the regulation of 
thalamocortical pathways between mouse and human, such as the lack of local interneurons 
in the rodent thalamus, might explain some of these differences. However, thalamocortical 
pathways represent a well-characterized system where the NCL disease progression and 
interventions to it can be effectively monitored. Thus, our study has enabled the use of these 




might be the Cln8mnd mouse visual system, where the relatively ample time frame between 
retinal and thalamocortical neuron loss could be utilized to target the NCL-related visual loss. 
However, therapies to prevent retinal cell loss need to be started very early. 
It is probable, however, that markedly more information on the CLN8 protein will be needed 
before the development of such therapies become feasible. The function of the CLN8 
protein was assessed in this study as well, and the link to galactolipid synthesis may open 
novel avenues for research. While this link indicates an oligodendrocyte-related function for 
CLN8, in other cell types CLN8 may execute other functions described in previous studies, 
such as regulation of calcium signaling and neurotransmitter balance. Indeed, robust 
involvement of glial cells in NCL pathogenesis suggests that the disease may involve 
abnormal function of both neurons and glial cells. These aspects are being dissected in other 
NCL models and in the future they should be tackled in CLN8 as well. 
In this study, two NCL subtypes with defects in two very different proteins were investigated 
in two animal models. It was possible to pinpoint similarities, such as the vulnerability of 
retina and the involvement of lipid metabolism regulation, as common phenomena in the 
pathogenesis of these two NCL diseases. Yet when comparing the results to other NCL 
models it is not obvious that there would be a common cellular pathway disrupted in all 
NCLs. The thalamocortical pathology of the Cln8mnd mouse differs from other NCL mouse 
models, and the cathD is linked to different genetic pathways in comparison to other NCL 
Drosophila models. In this regard, our study underlines the contradiction of NCLs: 
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